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Abstract 
Obstructive sleep apnea (OSA) syndrome is a condition characterized by the presence of complete or partial col-
lapse of the upper airways during sleep, resulting in fragmentation of sleep associated with rapid episodes of in-
termittent hypoxia (IH) and activation of the sympathetic nervous system and oxidative stress. (Dempsey et al. 
2010, 47–112; Bradley and Floras 2003, 1671–78; Bradley and Floras 2009, 82–93). OSA is associated with a 
broad spectrum of cardiovascular, metabolic, neurocognitive and comorbidities that appear to be particularly ev-
ident in obese patients (Floras 2014, 3–8; Luz Alonso-Álvarez et al. 2011, 0, 2–18; Marcus et al. 2012, e714–55; 
Sforza and Roche 2016, 99), while affecting both sexes in a different manner and varying in severity according to 
gender and age (Mokhlesi, Ham and Gozal 2016, 1162–69). In recent years, studies on OSA have increased con-
siderably, but in clinical practice it is still a highly underdiagnosed disease (Costa et al. 2015, 1288–92). To date, 
the gold standard for the diagnosis of OSA is nocturnal polysomnography (PSG). However, since it is not well 
suited to a large number of patients, also the Home Sleep Test (HST) is an accepted diagnostic method.   
Currently, the major aim of the research is to identify non-invasive methods to achieve a highly predictive, non-
invasive screening system for this category of subjects. The most recent reports indicate that research in this field 
has made significant progress in identifying possible biomarkers in OSA, using -OMIC approaches, particularly 
in the field of proteomics and metabolomics. In this review, we analyze a list of these OMIC biomarkers found 
in literature. 
 
Keywords: Obstructive sleep apnea, OMICs Sciences, Proteomics, Metabolomics, Lipidomics 
 
Incidence of OSA 
 
Despite its high prevalence and the high burden 
of morbidity, Obstructive Sleep Apnea (OSA) 
remains a significantly underdiagnosed disease 
worldwide. The Hypnolaus study estimated that 
the prevalence of moderate-to-severe sleep-
disordered breathing (≥15 events per h) was 
23.4% (95% CI 20·9–26.0) in women and 
49.7% (46.6–52.8) in (Heinzer et al. 2015, 310–
8) whereas according to the American Academy 
of Sleep Medicine (AASM 2016), only 20% of 
patients are diagnosed (about 6 million out of a 
total of 24 million) in US. The annual cost for 
an undiagnosed patient is estimated to be at 
around $5,500 (considering direct and indirect 
health costs), while it drops to $2,100 per year 
for diagnosed patients (Pietzsch et al. 2011, 
695–709). On this basis, it is evident that OSA 
is not only a serious health problem, but also a 
socio-economic problem.  
OSA is also becoming dangerously frequent in 
children, associated with adenotonsillar hyper-
trophy (Capdevila et al. 2008, 274–82; Lumeng 
and Chervin 2008, 242–52) as well as high rates 
of overweight and obesity in children in west-
ern countries. These trends will have disastrous 
long-term consequences for global health and 
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life expectancy if solutions are not taken as 
soon as possible to correct erroneous lifestyles 
from the earliest age (Bixler et al. 2009, 731–36; 
L Kheirandish-Gozal and Gozal 2012, 713–14; 
Li et al. 2010, 991–97; Marcus et al. 2012, e714–
55). 
These data also suggest that the only way to 
make sustainable the costs of OSA is the pre-
vention. 
 
Pathogenic mechanisms associated with 
OSA 
 
OSA is considered by far the most important 
form of sleep disturbance in breathing. It is 
caused by increased collapsibility or insufficien-
cy/loss of muscular dilation capacity of the up-
per airways, leading to repeated pharyngeal 
constriction (hypopnea) or closure (apnoea), 
and therefore resulting in oxyhemoglobin satu-
ration decreasing and partial pressure of carbon 
dioxide in arterial blood increasing (Jordan, 
McSharry and Malhotra 2014, 736–47).  
To date, the gold standard for the diagnosis of 
OSA is nocturnal polysomnography (PSG). 
This sleep examination utilizes electroenceph-
alography, electrooculography in both eyes, 
sub-mental electromyography, nasal airflow, 
snoring sounds, electrocardiography, thorac-
ic/abdominal movements, pulse oxygen satura-
tion and body position to measure various pa-
rameters. The PSG indices included were the 
apnoea-hypopnoea index 
(AHI) and oxygen desaturation index. Howev-
er, since it is not well suited to a large number 
of patients, also the Home Sleep Test (HST) is 
an accepted diagnostic method.   
To restore pharyngeal patency, patients experi-
ence recurrent awakenings, resulting in frag-
mented sleep, followed by reduced cognitive 
performance and, in some cases, diurnal sleepi-
ness episodes.  
High circumference values of the neck, hips 
and waist, hypertension (HTN), usual nocturnal 
snoring, as well as presence of a diabetic condi-
tion and a high body mass index (BMI) are of-
ten coexisting conditions in the OSA patient at 
the time of diagnosis. Among these comorbidi-
ties, obesity is often the worst aggravating fac-
tor, leading to the activation of molecular 
mechanisms that, if not effectively and early 
identified, may worsen the overall clinical pat-
tern of OSA.  
In the literature, substantial evidence suggests 
that OSA increases oxidative and inflammatory 
processes on animal models and humans. No-
tably, chronic hypoxia-reoxygenation cycles due 
to intermittent hypoxia (IH) have been shown 
to promote the activation of inflammatory 
pathways (Lavie 2003, 35–51), such as increased 
pro-inflammatory cytokine production, meta-
bolic dysregulation and insulin resistance 
(Christou et al. 2003, 105–9; Ciftci et al. 2004, 
87–91). In addition, several markers of reactive 
oxidative species (ROS) are increased in OSA, 
amplifying inflammatory cascades and endothe-
lial dysfunctions, such as the development of 
atherosclerosis, as well as promoting central 
nervous system dysfunctions (Lavie 2003, 35–
51; Wang, Zhang and Gozal 2010, 307–16; 
Shelley X.L. Zhang, Wang and Gozal 2012, 
1767–77; Zhou et al. 2016, 9626831). 
Many clinical researches have clearly demon-
strated that acute IH, associated with the activa-
tion of the sympathetic nervous system and 
strictly linked to a persistent condition of oxida-
tive stress, represent the pathogenetic modali-
ties for the manifestation of cardiovascular 
comorbidities in OSA, such as systemic arterial 
hypertension, left ventricular hypertrophy, car-
diac rhythm alterations and, following associat-
ed early alterations of the vasal endothelium, 
with increased risk of cerebral stroke and myo-
cardial infarction. (Alchanatis et al. 2002, 1239–
45; Ameli et al. 2007, 729–34; Amin et al. 2002, 
1395–99; Brooks et al. 1997, 106–9; Lesske et 
al. 1997, 1593–1603; Varadharaj et al. 2015, 40–
47; Jose M Marin et al. 2005, 1046–53; Mason 
et al. 2012, 1791–98) 
Other studies have shown clear and solid asso-
ciations between OSA and HTN (Nieto et al. 
2000, 1829–36; Peppard et al. 2000, 1378–84; 
Phillips and O’Driscoll 2013, 43–52; Ren et al. 
2016, 1264–70), type II diabetes (Lai et al. 2016, 
543–51; Plíhalová, Westlake and Polák 2016, 
S79-84; Reichmuth et al. 2005, 1590–95), stroke 
(Arzt et al. 2005, 1447–51; Campos-Rodriguez 
et al. 2013, 99–105; Ifergane et al. 2016, 1207–
12), heart failure (Pearse and Cowie 2016, 353–
61; Cowie 2016, 255–65; Shahar and Whitney 
2001, 19–25), coronary heart disease (Loo et al. 
2014, 631–36; José M. Marin et al. 2012, 2169–
76; Selim, Won and Yaggi 2010, 203–20), cardi-
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ac arrhythmias (Vizzardi et al. 2017, 490–500), 
cancer (Campos-Rodriguez et al. 2013, 99–105), 
metabolic, neurodegenerative and respiratory 
diseases (Al Lawati, Patel and Ayas 2009, 285–
93; Caples, Garcia-Touchard and Somers 2007, 
291–303; Tahrani, Ali and Stevens 2013, 631–
38; Young et al. 2008, 1071–78). 
However, the factors determining the damage 
in a given OSA patient are not yet well defined, 
so research is still ongoing (Bhattacharjee et al. 
2011, 313–23; Leila Kheirandish-Gozal and 
Gozal 2013, 338–43; Tan, Kheirandish-Gozal 
and Gozal 2014, 474–80). 
 
Searching for new biomarkers 
 
Given the difficulty of applying Home Sleep 
Test (HST) to the population as a screening 
system due to high cost and examination tim-
ing, researchers are currently focusing on iden-
tifying new biomarkers for the early diagnosis 
of OSA (Mullington et al. 2016, 727–36).  
In 1998, the National Institutes of Health Bi-
omarkers defined a biomarker as an objectively 
measured feature evaluated as an indicator of 
normal biological or pathogenic processes, or 
either pharmacological responses to a therapeu-
tic intervention (Strimbu and Tavel 2010, 463–
66). Biomarkers can therefore provide infor-
mation for diagnosis, prognosis, regression or 
response to treatment. In this scenario, the -
OMIC sciences, such as genomics, tran-
scriptomics, proteomics, and metabolomics, 
have been widely applied for finding new bi-
omarkers in various disease mechanisms. The 
identification of such molecules involved in the 
pathogenesis of OSA patients, can facilitate ear-
ly diagnosis and help to understand the com-
plex mechanism of this disease.  
In the case of sleep disorders and lung diseases, 
traditional biomarker research techniques have 
proved to be not particularly performing. Stud-
ies based on proteomics (Zheng et al. 2015, 
7046; Jurado-Gamez et al. 2012, 139–46; Gozal 
et al. 2009, 1253–61) and metabolomics 
(Auffray et al. 2010, 1410–16; Davies et al. 
2014, 10761–66; Weljie et al. 2015, 2569–74; 
Giskeødegård et al. 2015, 14843) techniques in-
stead, have proven to be more sensitive, alt-
hough, to date, the number of molecules poten-
tially available for clinical application in the 
OSA context is still limited.. The development 
of new technologies is therefore necessary, also 
to provide a greater understanding of the bio-
chemical mechanisms involved in OSA. 
 
Proteomics Approach 
 
The study of the proteome in OSA patients has 
been largely assessed. Many studies have re-
ported that OSA patients express increased lev-
els of mediators of the systemic inflammatory 
response. Zhang et al. (Huina Zhang et al. 
2018, 97–108) have performed, for the first 
time, a proteomic approach to detect protein 
profiles of serum extracellular microvescicle 
proteins in OSA patients and in a chronic IH 
rodent model. Extracellular microvescicles are 
vescicles released from cells into the extracellu-
lar fluid environment, including serum. Their 
potential utility in clinical diagnosis is well doc-
umented, since vescicles are reported to reflect 
the physiological or pathological status of the 
tissue from which they arise. They found 4 dif-
ferentially expressed proteins in serum extracel-
lular microvescicles of OSA patients compared 
to control: C-reactive protein (CRP), Haptoglo-
bin (HP), Fibronectin (FN1), and Platelet factor 
4 (PF4). In addition, Nadeem et al., (Nadeem et 
al. 2013, 1003–12) have confirmed expressed 
level of CRP and other systemic inflammatory 
mediators, including intercellular adhesion mol-
ecules (ICAM), coagulation factors (factor VIII, 
tissue factor), and significant increase in serum 
levels of tumour necrosis factor alpha (TNF-α), 
interleukin 1β (IL-1β) and interleukin 6 (IL-6) 
were observed in patients with OSA. The ex-
cessive infiltration of inflammatory cells is also 
highlighted by the formation of subepithelial 
edema in OSA patients seen by histology. 
Among these proteins, circulating CRP is an 
important predictive factor of cardiovascular 
risk involved in the onset and progression of 
atherosclerosis. Its pro-inflammatory and 
proaterogenic properties have been found in 
endothelial cells, muscle cells, both smooth and 
striated, and macrophages.  Its levels, as well as 
those of IL-6, are strongly associated with oxi-
dative stress or anoxia (Nena et al. 2012, 181–
86; Huina Zhang et al. 2018, 97–108). A simi-
larly important role in the clinical picture of the 
OSA patient is the high level of TNF-α ob-
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served; it is in fact a pro-inflammatory cytokine 
with an important role in the defence of the 
host, which at the same time mediates the onset 
of a series of pathological processes such as 
atherosclerosis, septic shock and autoimmune 
diseases. The release of TNF-α is mediated by 
IL-6, as well as by other pro-inflammatory cy-
tokines such as IL-2, IL-2, IFN-γ and by TNF-
α itself through a positive feedback process 
(Aihara et al. 2013, 597–604; Dyugovskaya et al. 
2011, 154–62). 
A whole-genomic microarrays recently carried 
out by Yung-Che et al., has shown angiomotin 
(AMOT), pleckstrin homology, MyTH4 and 
FERM domain containing H3 (PLEKHH3), 
adenosine deaminase RNA specific (ADAR), 
baculoviral IAP repeat containing 3 (BIRC3), 
and galectin 3 (LGALS3) proteins over-
expressions in the treatment-naïve OSA pa-
tients (Chen et al. 2017). LGALS3 has shown to 
be involved in cancer, inflammation and fibro-
sis, heart disease, and stroke. Studies have also 
proved that the expression of galectin-3 is im-
plicated in a variety of processes associated with 
heart failure, including myofibroblast prolifera-
tion, fibrogenesis, tissue repair, inflammation, 
and ventricular remodelling (Henderson and 
Sethi 2009, 160–71; Sharma et al. 2004, 3121–
28; Liu et al. 2009, H404–12). 
Expression of AMOT in endothelial cells and 
its level is associated with proliferation and in-
vasion of breast tumours (Lv, Lv and Chen 
2015, 1938–46). 
ADAR are double chain RNA editing enzymes 
responsible for post-transcriptional modifica-
tion of mRNA transcripts by changing the nu-
cleotide content of the RNA. The conversion 
from A to I in the RNA disrupt the normal A:U 
pairing which makes the RNA unstable (Samuel 
2011, 180–93). ADAR is considered to be in-
volved in the insurgence of cancer (9). Studies 
in sleep field, revealed also that the ADA G22A 
polymorphism (c.22G>A, rs73598374) is asso-
ciated with fewer awakenings throughout the 
night, and a higher duration of slow wave sleep 
(SWS), as compared to the normal ADA G22G 
genotype (Milrad et al. 2014). 
BIRC3 is a downstream effector of the ubiqui-
tous hypoxia-inducible factor (HIF-1α) that is 
involved in pro-survival and inflammatory re-
sponses induced by the docosahexaenoic ac-
id/neuroprotectin D1 pathway under oxidative 
stress in an ischemia-reperfusion stroke model. 
HIF-1 α functions as a principle regulator activ-
ity of cellular and systemic homeostatic re-
sponse to hypoxia. This heterodimer composed 
of an alpha and a beta subunit can activate the 
transcription of many genes, including those 
involved in energy metabolism, apoptosis, angi-
ogenesis, and other genes whose protein prod-
ucts increase oxygen delivery and facilitate met-
abolic adaptation to hypoxia. Since many stud-
ies have shown that OSA is associated with an 
imbalance between oxidant production and an-
tioxidant activity, this fact, combined with an 
overabundance of oxidants can be linked to the 
multifactorial aetiology of metabolic disorders, 
including insulin resistance (Henriksen, Dia-
mond-Stanic and Marchionne 2011, 993–99).  
Almendros et al. (Almendros et al. 2018, 272) 
examined the correlation between HIF-1α fac-
tor and vascular endothelial growth factor 
(VEGF) expression in patients with cutaneous 
melanoma. Interestingly, they found that in a 
large prospective study, the expression of HIF-
1α was an independently factor associated with 
nocturnal IH measures of respiratory disturb-
ance during sleep in patients affected by cuta-
neous melanoma (Almendros et al. 2018, 272), 
this means that it has a significant contribution 
to the disease. Notably, the risk of melanoma 
was significantly higher in patients with OSA 
(HR = 1.14, 95% CI 1.10-1.18), along with 
pancreatic and kidney cancer (Gozal, Ham and 
Mokhlesi 2016, 1493–1500).  
In the recent years, other potential association 
between OSA and cancer have been reported, 
principally ascribed to IH effect on tumour bi-
ology (Gozal, Farré and Nieto 2016, 43–55; 
Gozal, Ham and Mokhlesi 2016, 1493–1500; 
Martínez-García, Campos-Rodriguez and Barbé 
2016, 451–63; Almendros et al. 2014, 593–601).  
A significant correlation between OSA and in-
creased cardiovascular risk and HTN is strongly 
reported in literature (Sjöström et al. 2002, 602–
7; Drager et al. 2010, 1135–39; Gami et al. 
2004, 364–67; Sin et al. 1999, 1101–6). Mass-
spectrometry was performed on salivary sam-
ples of OSA patients with cardiovascular dis-
eases (CVD) compared to non-CVD OSA pa-
tients (Zheng and Li 2014, 7046). A panel of 11 
biomarkers were identified to be differentially 
expressed between the two groups. They found 
that the alpha-2-HS-glycoprotein (AHSG) pep-
Luana Conte, Marco Greco, Domenico Maurizio Toraldo, Michele Arigliani, Michele Maffia, Michele De Benedetto 
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tide level was significantly lower in OSA-CVD 
group compared to non-CVD group. Reduced 
level of AHSG was already found in severe 
OSA patients (Barceló et al. 2012, 1046–48) and 
at metabolic level  (Dyugovskaya et al. 2011, 
154–62) (see next chapter). AHSG protein is 
synthesized by hepatocytes and it is involved in 
severel process such as brain and bone for-
mation and endocytosis. Interestingly, lack of 
this protein is involved in leanness.  
Another studied association between OSA and 
HTN was performed by Koyama et al. (Koya-
ma et al. 2009, 1107–11). They studied 266 
OSA patients on respect to the Angiotensin 
converting enzyme (ACE) gene. This gene con-
tains an insertion/deletion polymorphism on 
the intron 16 characterized by a 287-bp DNA 
sequence (Alhenc-Gelas et al. 1991, 33–39). 
They showed that ACE II homozygote geno-
type protects from severe OSA in HTN pa-
tients.  
 
Metabolomics Approach 
 
The field of metabolomics, and the consequent 
search for potential biomarkers in OSA pa-
tients, is beginning to be explored only in re-
cent years. The lipidomic profile in OSA pa-
tients reported in literature, mainly reveals alter-
ation in the phospholipid biosynthesis and fatty 
acids expression. One of the major study 
through mass-spectrometry technique has al-
lowed to identify, both at a serum and urinery 
level, as many as 103 proteins differently ex-
pressed in adult OSA patients compared to 
controls, all potentially associated with imbal-
ances in lipid metabolism and alterations in the 
vascular system (Jurado-Gamez et al. 2012, 
139–46). Among phospholipids, glycerophos-
phocholines (PC), lysophosphatidylcholines 
(LPE), glycerophosphoethanolamines (PE), 
lysophosphatidylethanolamine (LPA), phos-
phoserine (PS), and lysophosphatidic acids, 
along with glycerophosphates (PA), monoacyl-
glycerophosphocholines, lyso-phosphocolyne 
(LPC) and sphingomyelin (SM) classes were 
found to be up regulated in patients with OSA 
compared to control (Ferrarini et al. 2013; Leb-
kuchen et al. 2018, 11270). Increased PC ex-
pression at salivary level was also reported 
through a LC-MS/MS methods (Kawai et al. 
2013; Engeli et al. 2012, 2345–51).  
Fatty acids alteration was also detected in OSA. 
Among those that significantly increased among 
OSA group compared to normal subjects, cir-
culating anandamide (AEA), 2,4-
dihydroxybutyric acid, 2-hydroxy-3-
methylbutyric acid, 3,4-dihydrxoybutyric acid, 
6-aminocaproic acid, pentanoic acid, and 
glyceraldehyde, 3-methyl-3-hydroxybutyric acid, 
and 4-hydroxypentenoic acid were up-
regulatetd, whereas the bile acid and gly-
cochenodeoxycholate-3-sulfate (GCDCA-3-
sulfate) decreased (Papandreou 2013, 569–72, 
Kawai et al. 2013; Engeli et al. 2012, 2345–51). 
Other groups, through GC-LC techniques, 
found that palmitoleic and oleic acid levels were 
lower, while stearic acid levels were higher in 
the tonsillitis tissue of infant control subjects, 
compared to the hyperplastic tissue typical of 
the diseased counterpart (Ezzedini et al. 2013, 
1008–12).  
Other research groups observed that in OSA 
patients, levels of 1/2-arachidonoylglycerols 
(AG), and oleoyl ethanolamide (OEA) in plas-
ma where higher when compared to controls. It 
was interesting to note that also AA arachidonic 
acid (AA) concentrations and eicosanoids (Fer-
rarini et al. 2013; Lebkuchen et al. 2018, 11270) 
were up-regulated in OSA patients, suggesting a 
role for the endocannabinoid system in regulat-
ing blood pressure in patients with high risk 
OSA for HTN and CVD (Kawai et al. 2013; 
Engeli et al. 2012, 2345–51). 
The endocannabinoid system is, in fact, based 
on lipid molecules produced by the body in re-
sponse to various stimuli that bind specific 
membrane receptors associated with the protein 
G and called cannabinoid receptors type 1 and 
2 (CB1 and CB2) (Pagotto, Vicennati and 
Pasquali 2008, 74S-82S). The endocannabinoid 
system represents a neuromodulation system, 
playing an action in the control of pain at the 
level of the central nervous system, in the regu-
lation of cell proliferation processes and in the 
modulation of the immune response. Interest-
ingly, it also seems to play a role in the mecha-
nisms that modulate appetite and therefore 
obesity (Di Marzo et al. 2001, 822–25; Crox-
ford and Yamamura; Marsicano et al. 2002, 
448–56; Engeli et al. 2012, 2345–51; Salzet et al. 
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2000, 4917–27). The endocannabinoid system 
also plays an important role in the release of ad-
ipokines. Recent research has shown that the 
pharmacological blockade of CB1 by an antag-
onist, named Rimonabant, stimulates the re-
lease of adiponectin, that is normally inhibited. 
Adiponectin is a circulating hormone secreted 
by adipose tissue, with antiaterogenic and anti-
diabetic properties that can reduce liver glucose 
production, as well as suppress lipogenesis and 
activate the oxidation of fatty acids (Matias et 
al. 2006, 3171–80; Jbilo et al. 2005, 1567–69). 
The endocannabinoid ways of regulating me-
tabolism are still only partially understood, de-
spite the fact that their role in controlling hun-
ger and satiety acts mainly in hypothalamic 
structures through the activation of neurons 
capable of producing neuropeptides with 
pressizing and anorexic action (Park and Bloom 
2005, 228–33). Alterations to the endocanna-
binoid system therefore affect and alter the en-
ergy metabolism of the body and the homeo-
stasis of lipids, as suggested by Di Marzo and 
Matias, the first to formulate the increasingly 
true hypothesis that obesity can be associated 
with a pathological hyperactivation of the en-
docannabinoid system (Di Marzo and Matias 
2005, 585–89). All these conditions can be as-
sociated with an increased risk of cardiometa-
bolic diseases such as type 2 diabetes, dyslipi-
daemia, arterial hypertension, myocardial infarc-
tion and stroke, conditions normally found in 
OSA patients. 
 
Mediators involved in systemic inflammatory 
response and oxidative stress were also report-
ed in OSA. Among the metabolites associated 
with oxidative stress, the 15-F2t-urinary iso-
prostane, one of the most sensitive metabolites 
correlated to lipid peroxidation, is positively 
linked to the thickness of the intimo-media ca-
rotid tunic (Paci et al. 2000, S87-91). These 
molecules were shown to be a specific, chemi-
cally stable, quantitative marker of oxidative 
stress in vivo. In particular, F2t-isoprostanes are 
prostaglandin isomers synthesised in vivo 
through the free radical catalysed peroxidation 
of AA in biological membranes, independently 
of the activity of cyclo-oxygenase (Morrow et 
al. 1990, 9383–87). Increased urinary excretion 
or plasma concentrations of 15-F2t-isoprostane 
has been observed in many conditions includ-
ing smoking, diabetes, and cardiovascular dis-
eases (Nonaka-Sarukawa et al.). 
Another important biomarker of oxidative 
stress, Malondialdehyde (MDA), is significantly 
higher in concentrations detected in patients 
with OSA than in controls (Denis Monneret et 
al. 2010, 619–25; Dikmenoğlu et al. 2006, 255–
61). MDA is the result of lipid peroxidation of 
polyunsaturated fatty acids. It is an important 
product in the synthesis of thromboxane A2 in 
which cyclooxygenase 1 or cyclooxygenase 2 
metabolizes AA into prostaglandin H2. ROS 
degrade polyunsaturated lipids, forming MDA 
(Gaweł et al. 2004, 453–55). This compound is 
a reactive aldehyde and is one of many reactive 
electrophilic species that cause toxic stress in 
cells, reacts with deoxyadenosine and deoxy-
guanosine in DNA, forming DNA adducts and 
can be used as a biomarker to measure the level 
of oxidative stress in an organism (Pryor and 
Stanley 1975, 3615–17; Marnett 1999, 83–95). 
 Arguably, the tricarboxylic acid cycle (TCA) 
and its mediators, tend to increase in OSA (Xu 
et al. 2016, 30958), suggesting augmenting of 
the oxidative stress.  
 
Among Metabolites that find space as pro-
inflammatory markers, Stanke-Labesque et al. 
have found Leucotriene E4 (U-LTE4), an in-
flammatory molecule associated with cysteinyl 
leukotriene production, whose elevation in uri-
nary concentration has been demonstrated in 
patients with OSA. Recently, Gautier-Veyret 
and his group have shown that this pathway ac-
tivation contributes to OSA-induced athero-
genesis and its blockade could represent a new 
therapeutic target for reducing CVD (Gautier-
Veyret et al. 2018, 311–19). It is also interesting 
to note that Continuous Positive Airway Pres-
sure (CPAP) treatment, a respiratory ventilation 
method mainly used in the treatment of sleep 
apnea, reduces the urinary concentration of U-
LTE4 by up to 22%, but only if the treatment is 
carried out in patients with a normal BMI 
(Stanke-Labesque et al. 2009, 364-370.e2).  
Arguably, CPAP treatment reduces also serum 
levels of Homocysteine (Hcy) by almost 30%, 
that, along with plasma levels, were found to be 
significantly higher in patients with OSA com-
pared to those of the controls (Ezzedini et al. 
2013, 1008–12; Papandreou 2013, 569–72, 
Fletcher et al. 1987, 35–44; Findley et al. 1988, 
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556–61). In addition, neural-like cell exposure 
to Hcy for a period of 5 days resulted in a 4.4-
fold increase in ROS production (Currò et al. 
2014, 1485–95). Hcy is known to mediate ad-
verse effects on cardiovascular endothelium 
and smooth muscle cells with resultant altera-
tions in subclinical arterial structure and func-
tion (Ganguly and Alam 2015, 6), leading to 
CVD and its complications, such as heart at-
tacks and strokes (Baszczuk and Kopczyński 
2014, 579–89). Moreover, hyperhomocyste-
inemia leads to enhancement of the adverse ef-
fects of risk factors like HTN, smoking, lipid 
and lipoprotein metabolism, as well as promo-
tion of the development of inflammation 
(Baszczuk and Kopczyński 2014, 579–89). An-
other study demonstrated that Hcy is capable of 
initiating an inflammatory response in vascular 
smooth muscle cells by stimulating CRP pro-
duction, which is mediated through NMDAr-
ROS-ERK1/2/p38-NF-κB signal pathway 
(Pang et al. 2014, 73–81). CRP expression was 
also found to be altered in the proteome of 
OSA patients (see previous chapter).  
Some studies also suggest that elevated Hcy 
levels may be associated with alterations in 
mental health such as cognitive impairment, 
dementia, depression, Alzheimer’s and Parkin-
son’s disease (Faeh, Chiolero and Paccaud 
2006, 745–56; Carmel and Jacobsen 2001) 
through its capacity to act as a neurotransmit-
ter. In particular, Hcy may act either as a partial 
agonist at glutamate receptors or as a partial an-
tagonist of glycine co-agonist site of the 
NMDA receptor, therefore in the presence of 
normal glycine levels and normal physiological 
conditions, Hcy does not cause toxicity but in 
case of a head trauma or stroke, there is an ele-
vation in glycine levels in which instance the 
neurotoxic effect of Hcy as an agonist out-
weighs its neuroprotective antagonist effect. 
This neuronal damage following a stroke has 
been attributed to the over stimulation of excit-
atory amino acids such as glutamate and aspar-
tate through activation of NMDA receptors 
(Ganguly and Alam 2015, 6; Carmel and Jacob-
sen 2001). Ganguly et al. (Ganguly and Alam 
2015, 6) have investigated how Hcy is able to 
selectively stimulate the release of these excita-
tory amino acids in stroke and they concluded 
that they may trigger the release of catechola-
mine, resulting into detrimental effect in brain 
and cardiovascular system. Interestingly, in 
OSA patients, glutamate metabolites were also 
found to be significantly altered  (Xu et al. 
2016, 30958). 
The study of catecholamine metabolites and de-
rivatives as potential predictors of the onset of 
the pathological process seems particularly 
promising. Fletcher et al. (Fletcher et al. 1987, 
35–44), for example, observed that norepineph-
rine (NE) and normethanephrine levels were 
significantly higher in the urine of patients with 
OSA than those found in obese HTN controls, 
as well as epinephrine (E) levels, at the plasma 
level (Findley et al. 1988, 556–61). Data subse-
quently confirmed by Paci et al. (Paci et al. 
2000, S87-91), who also found higher levels of 
dopamine (DA) in the comparison of 10 male 
patients with OSA and 11 controls. HPLC ob-
servations revealed a significant increase in all 
urinary catecholamine in OSA children, and 
that the levels of NE and E during the night are 
strongly related to the severity with which they 
manifest the altered phenotype. Paik et al (Paik 
et al. 2014, 517–23), after studies carried out us-
ing GC-MS to detect metabolites of urinary 
neurotransmitters, demonstrated that homo-
vanillic acid (HVA) and 3,4-
dihydroxyphenylacetic acid (DOPAC), both 
dopamine metabolites, were increased in sleepy 
patients with OSA, suggesting that excessive 
daytime sleepiness in these subjects is probably 
caused by an increase in night-time activity of 
the dopaminergic and sympathetic systems 
(O’Driscoll et al. 2011, 483–88). Although this 
theory seems intriguing, the results of several 
other studies question it. Paci et al. have report-
ed that E and DA levels did not vary signifi-
cantly between OSA patients and controls. In 
addition, the results of the studies of Gislason 
et al, found 5-hydroxyindo-lacetic acid (5-
HIAA), HVA and 3-methoxy-4-hydroxyphe-
glicolenyl glycol (MHPG) in the cerebrospinal 
fluid of 15 patients with OSA and 18 controls; 
however, even in this case, the levels of all these 
biomarkers were similar in patients with OSA 
and control subjects (Paci et al. 2000, S87-91; 
Gislason et al. 1992, 784–86).  
The inconsistency of the results obtained from 
the studies on catecholamine metabolites in pa-
tients with OSA may be due to various factors 
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such as the heterogeneity of the analytical plat-
forms used by the various research groups, the 
different biological matrices taken into account, 
the small size of the samples, and the different 
protocols used for sample collection. Elements 
that may also affect the reproducibility of stud-
ies.  
 
The first studies aimed at finding differentially 
expressed metabolites at the urinary level in 
children with OSA, was carried out by Krishna 
et al. (Krishna et al. 2006, 221–27). They adopt-
ed a mass-spectrometry technique on a cohort 
of 22 subjects, who demonstrated an alteration 
in the glomerular and tubular filtration of the 
kidneys, compared to the healthy counterpart. 
High levels of proteins such as jasmine, per-
lecan (a heparan sulfate proteoglycan), albumin, 
and immunoglobulin were detected in urine. 
Result which suggested increased catabolic ac-
tivity of some proteins in OSA patients (Krish-
na et al. 2006, 221–27). Also in the same period, 
Shah et al. identified at the silky level, three pro-
teins of 5896, 3306 and 6068 kDa respectively 
differently expressed in pathological children, 
capable of discriminating the latter from healthy 
patients with 90% specificity and 93% sensitivi-
ty (Shah et al. 2006, 466–70). Three years later, 
Gozal et al., through a method based on the use 
of 2D-DIGE-MS, were able to identify 16 me-
tabolites differently expressed in the urine of 
OSA patients compared to controls. In particu-
lar, the analysis of concentrations of some of 
these, including uromodulin, urocortin-3, oro-
somucoid-1, and kallikrein, were able to identify 
the pathogenic phenotype with a sensitivity of 
95% and even a specificity of 100% (Gozal et 
al. 2009, 1253–61).  
The contribution of Seetho et al. and Zeng et 
al. in the field of research into potential OSA 
biomarkers was extremely interesting, with the 
first, focusing on the research of polypeptides 
using the urine of obese OSA patients used as a 
biological matrix, and the second, looking for 
proteins differently expressed between OSA pa-
tients suffering from CVD and not, in saliva. 
The work of the two groups allowed identifying 
27 potential biomarkers, fibrinogen alpha chain 
(FGA), tubulin alpha-4A chain (TUBA4A) and 
AHSG. More specifically, AHSG has been 
shown to be expressed at lower levels in OSA 
frameworks associated with changes in cardio-
vascular function (Seetho et al. 2014, 1104–15; 
Zheng and Li 2014, 7046). 
 
Alteration in the amino acid biosynthesis were 
also reported in OSA through metabolomics 
approach. Xu et al. identified 21 differentially 
expressed urinary metabolites among simple 
snoring group and control, including aspartyl-
serine, isoleucine-threonine (Ile-Thr), and me-
thionine, whereas levels of 3-hydroxyanthranilic 
acid and 5-hydroxytryptophan decreased. Hy-
droxyprolyl-methionine, hypoxanthine, Ile-Thr, 
indole-3-acetamide, isoleucine, lactic acid, myo-
inositol, pentanoic acid, threitol, threoninyl-
methionine, trimethylamine N-oxide (TMAO), 
uridine, and valine were consistently higher or 
lower (Xu et al. 2016, 30958). Other groups 
have also reported that methylcysteine and ser-
ine decreased in OSA condition (Kawai et al. 
2013; Engeli et al. 2012, 2345–51).  
 
The metabolomics profiling of spermine bio-
synthesis, indoles and tryptophan metabolism, 
tyrosine metabolism as well as porphyrin me-
tabolism were also altered significantly  (Xu et 
al. 2016, 30958; Papandreou 2013, 569–72).  
 
Conclusions 
 
OSA is characterized by recurrent episodes of 
collapse of the upper airways during sleep, 
which are reflected in a desaturation of haemo-
globin that leads to the awakening of affected 
subjects. The chronic IH registered in this con-
dition, leads the body to enact molecular adap-
tations to the low-oxygen conditions to which it 
is subject (Young et al. 1993, 1230–35). Despite 
this, sleep fragmentation results in a dangerous 
condition of excessive sleepiness during the rest 
of the day. In addition to the long-term prob-
lems that are listed, this sleep fragmentation en-
tails a daily danger for the individual linked to 
the increased risk of road or work accidents. 
The body responds to chronic fatigue through 
compensatory mechanisms that evoke inflam-
matory responses, hyperactivation of the sym-
pathetic system and alteration of endothelial 
function, like regulation of tight junctions; these 
events have an important role in promoting the 
onset of atherosclerosis and, in the long run, of 
cardiovascular and cerebrovascular diseases 
(Nadeem et al. 2013, 1003–12). 
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Recent studies show also a significant correla-
tion between OSA and metabolic and neu-
rocognitive risk (Sjöström et al. 2002, 602–7; 
Drager et al. 2010, 1135–39; Gami et al. 2004, 
364–67; Sin et al. 1999, 1101–6), as well as an 
association with cancer mortality. 
In literature, proteomics and metabolomics ap-
proaches were used to detect change in physio-
logical or pathological status of OSA patients 
compared to controls, in order to find out new 
mediators that can be used as biomarkers of the 
disease. Notwithstanding OSA is a ‘quite new’ 
emerging disease, there are lots of proteins and 
metabolites that arise during disease, in particu-
lar those involved in inflammation and oxida-
tive stress, in line with the clinical IH that pa-
tient undertaken in OSA disease.  
Lipid dismetabolism in OSA reflects alteration 
in phospholipids biosynthesis, steroidogenesis 
and fatty acids expression. This may influence 
the cell membrane formation, incrementing li-
pid uptake, atherogenesis and inflammation.  In 
addition, alterations in amino acids, nucleic acid 
and some mediators that act as neurotransmit-
ters, such as Hcy and the endocannabinoid sys-
tem were seen in OSA patients, suggesting an 
increased risk of cardiometabolic diseases such 
as type 2 diabetes, dyslipidaemia, arterial hyper-
tension, myocardial infarction and stroke, con-
ditions normally found in OSA patients. 
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Abstract 
Graph theory has been extensively applied in the study of proteins, although few applications still exist on bio-
molecules like aptamer-protein complexes, whose structure is in silico obtained. Aptamers represent a challeng-
ing field of research, especially for their involvement in therapy, diagnosis and early detection of illness; further-
more, the in vivo procedures to synthetize them are quite expensive and more time-consuming than those in sili-
co. This paper is focused on the question if and how general network parameters are able to anticipate some fea-
tures of those biomolecules. The rationale resides in the fact that, studying a large set of aptamer-angiopoietin 
complexes, two different types of conformers are manifest. Both types could be present in a real sample with 
their relative amount reflecting, in a typical population shift scenario, the affinity of the whole sample.  
 
Keywords: graph theory, in silico structure of biomolecules, aptamer-angiopoietin complex.   
 
 
Introduction 
 
In recent years, several techniques have been 
developed for the early diagnosis and the ongo-
ing follow up of several fatal diseases. The main 
prerequisites are: to be minimally invasive, to 
make use of biodevices based on nanosized ma-
terials, to show high biocompatibility and long-
term stability. Aptamers are small fragments of 
ssDNA or RNA, entitled to play a primary role 
in this challenge. They are artificially assembled 
for achieving high binding affinity to their tar-
gets (from proteins to simple ions). Further-
more, low dimension, short half-time, low im-
munogenicity and production costs make them 
formidable competitors of antibodies in both 
diagnosis and therapy. 
Nevertheless, it has to be pointed out that ac-
ceptance and use of aptamers in industry and 
by (bio)pharmaceutical companies is still rare 
(Famulok and Mayer 2014). The reason is pri-
marily linked to the lack of information con-
cerning the binding mechanism with target, in-
trinsically interesting, since a single referencing 
model does not exist and different possible 
scenarios have been drawn to explain the for-
mation of aptamer-receptor complex, including 
conformational shift, induced fit, lock and key 
(Koshland 1995; Kinghorn et al. 2017). Fur-
thermore, the in vivo exploration (Tuerk and 
Gold 1990) is quite difficult and can be ex-
tremely time-consuming. Public data, such as 
the European Bioinformatics Institute (EMBL-
EBI https: //www.ebi.ac.uk), provide free and 
open access to a range of bioinformatics appli-
cations for sequence analysis, but, mainly for 
aptamers, crystallographic characterization is 
still in its infancy. 
In parallel with the in vitro techniques, many 
computational procedures have been developed 
for predicting 3D structure from sequence in-
formation. In general, aptamer-protein com-
plexes are obtained passing through two main 
steps: first, aptamers have to be folded, thus the 
folded (3D) sequences have to be docked with 
the protein. Docking tools provide a ranking 
for the obtained configurations, taking into ac-
count many parameters, such as the interaction 
energies between the two molecules, the 
desolvation and solvation energies associated 
with the interacting molecules and the entropic 
factors that occur upon binding (Trott and Ol-
son 2010). 
However, the ranking assignment continues to 
be an open question (Kaufmann et al. 2017; 
Cataldo et al. 2018). In a recent investigation 
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(Cataldo et al. 2019), a new estimate was pro-
posed to complement the computational rank-
ing outcomes, based on maximum likelihood 
criteria of the topological and electrical proper-
ties of aptamer-protein complexes. It was ap-
plied on a set of anti-angiopoietin(Ang2) ap-
tamers, whose performances are known from 
the experiments (Hu et al. 2015).  From the 
analysis, two principal types of conformers 
were identified and a deep discussion of the 
possible scenarios linked to those results was 
performed. The present paper aims to formu-
late a novel and simplified procedure to analyse 
all those different conformers, looking at topo-
logical characteristics of the networks repre-
senting the biomolecules. We show that im-
portant features can be extracted, another type 
of arrangement aptamer-Ang2 is observed, and 
finally, we suggest on which flaws and imper-
fection research has to focus its attention. 
 
Background 
 
Angiopoietins are part of a family that have a 
prominent role in vascular disease (Fagiani and 
Christofori 2013) and vasculature upregulation 
of many types of tumours (White et al. 2003). 
The most extensively studied angiopoietins are 
Ang1 and Ang2, especially for their involve-
ment in cancer therapy. Ang2 is a compact pro-
tein with three domains, named A, B, and P. 
The P domain is the most divergent (Figure 1), 
both in sequence and in structure, among the 
fibrinogen homologs, and it is the site of ligand 
binding for most fibrinogen domain-containing 
proteins (Barton et al. 2005). 
 
Figure 1. Hair  (left) and Belt  (right) aptamer-Ang2 
conformers: in the Hair, the binding site of the aptamer 
(yellow) is primarily the P domain (green), while in the 
Belt, the binding site of the aptamer (yellow) is also in 
the B domain (blue). 
 
Hu et al. (2015) selected and studied the affinity 
properties of a set of five sequences: two of 
them were natural anti-Ang2 and anti-Ang1 ap-
tamers, while the other three were mutated se-
quences; the affinity for the target was evaluat-
ed by means of measurements with a surface 
plasmon resonance (SPR) biosensor. Conflict-
ing results concerning the performances of the 
sequences were observed; in particular, the se-
quence with the best computational rank 
among the five considered (named 
Seq2_12_35) was one of the worst performing 
in experiments.  
In (Cataldo et al. 2018) a procedure to cope 
with the problem of docking of ligands charac-
terized by a large number of flexible freedom 
degrees was presented, by using as case-study 
the five aptamers proposed in (Hu et al. 2015). 
The 3D structure of the aptamers was obtained 
by using the free SimRNA software (Boniecki 
et al. 2015), docking was performed by means 
of rigid or flexible roto-translations in the free 
AutoDock Vina tool (Trott and Olson 2010). 
For scoring the complexes, a single and ener-
getic quantity called “effective affinity” (EA) 
was proposed, putting together the docking en-
ergy provided by AutoDock Vina and the   
SimRNA energies. 
In (Cataldo et al. 2019) a novel kind of scoring 
was addressed, starting from the same aptamers 
in (Hu et al. 2015). The study revealed a differ-
ent type and abundance of conformers, which 
would best represent each aptamer-protein 
complex. The one, named Hair, mimics the 
binding with its natural protein target (Tie2), 
the other, named Belt, hangs the protein also 
far from the original binding domain (Figure 1).  
The results highlighted that: a. the effective af-
finity (Cataldo et al. 2018) seems not to be able 
to discriminate between these two types of con-
formers, because their values are quite similar; 
b. the Ang2-specific aptamer prefers Hair con-
formers; c. the Ang1-specific aptamer prefers 
Belt conformers; d. mutated sequences do not 
show a distinct preference. In other terms, it 
seems that the Hair conformer characterizes the 
high affinity complexes, while the Belt con-
former characterizes the low affinity complexes.  
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Graph analysis 
 
Starting from some seminal papers (Watts and 
Strogatz 1999; Albert and Barabási 2000), graph 
analysis has received increasing attention with 
applications to several fields of research, from 
physics to psychology. In fact, graph analysis is 
able to capture part of the complexity, which is 
inherent in most of natural phenomena. The 
inner idea is to explain multiscale-multiphase-
many body phenomena by using interactions, 
thus in terms of networks.  
Network has a topological structure given by 
the associated graph G(N,L), with N the node 
set and L the link set (Van Mieghem et al 2014).  
In proteins, the Cα atom of each amino acid is 
considered as a node, and two amino acids are 
considered nearest neighbors if the distance be-
tween their Cα atoms is less than an assigned 
threshold value. This distance or cut-off radius 
RC is a free parameter; whose tuning produces a 
graph more or less connected (Alfinito et al. 
2017). Once all the Euclidean distances be-
tween the couples of Cα atoms are calculated, a 
distance matrix is obtained; from the distance 
matrix, the graph description of the network is 
represented through its adjacency matrix A of 
size N x N, with element: 
ai,j    = 1 (there is a link), if the distance between 
node i and j  is less than the assigned RC;  
ai,j    = 0 (there is no link), if the distance be-
tween node i and j is greater than the assigned 
RC.  
We assume that no self-loops (hence ai,i = 0) 
and no overlapping links exist, i.e. there cannot 
be more than one link between ai,j , therefore, 
we deal with a simple graph (Albert and Barabási 
2000).  
Among the various parameters that measure the 
graph characteristics, we point out on the fol-
lowing, giving a short definition. 
 
Degree: the degree k is defined as the total 
number of network connections. The average 
of ki over all i nodes is called the average degree 
[k] of the network. The spread in node degree 
is characterized by a distribution function P(k), 
which gives the probability that a randomly se-
lected node has exactly k links (Wang 2002). 
 
Assortative mixing and coefficient of as-
sortativity (r): a network is said to show ‘as-
sortative mixing’, if the high-degree nodes tend 
to be connected with other high-degree nodes, 
and ‘disassortative’ when the high-degree nodes 
tend to connect with low-degree nodes. It is the 
Pearson correlation coefficient of the degrees at 
either ends of a link and lies in the range 
−1≤r≤1; r = 1 means perfect assortativity, r = 
−1 means perfect disassortativity, r = 0 means 
no assortativity (random linking). If a network 
has perfect assortativity (r = 1), then all nodes 
connect only with nodes with the same degree. 
   
Diameter and Shortest path length and av-
erage path length: the diameter D of a net-
work is the maximal distance between any pair 
of its nodes. The distance Lij between two 
nodes i and j is defined as the number of links 
along the shortest path connecting them. Then, 
the average path length L of the network is de-
fined as the distance between two nodes, aver-
aged over all pairs of nodes. L determines the 
effective size of a network, i.e. the typical sepa-
ration of pairs of nodes (Wang 2002). 
  
Clustering coefficient: clustering coefficient C 
can be defined as the average fraction of pairs 
of neighbors of a node, which are also neigh-
bors of each other. Suppose that a node i in the 
network has ki links, which connect it to ki oth-
er nodes. These nodes are the neighbors of 
node i. Clearly, at most ki(ki −1)/2 links can ex-
ist between them, and this occurs when every 
neighbour of node i is connected to every other 
neighbour of node i. The clustering coefficient 
Ci of node i is defined as the ratio between the 
number Ei of links that actually exist between 
these ki nodes and the total number ki(ki 
−1)/2, namely 
 
The clustering coefficient C of the whole net-
work is the average of Ci over all i (Wang 
2002). 
 
Largest eigenvalue (lev) depends on the high-
est degree in the graph. For any k regular graph 
G (a graph with k degree on all the vertices), 
the eigenvalue with the largest absolute value is 
k. Generally, lev increases if the graph contains 
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vertices of high degree, and decreases gradually 
from the graph with highest degree 6 to the one 
with highest degree 2 (Vishveshwara 2002).  
 
Materials and Methods 
 
In Table 1 are listed the five different RNA-
aptamers employed for the research, they are 
the same sequences described in (Hu et al. 
2015).  
 
Name Sequence 
Seq1 AAAAAACUAGCCUCAU-
CAGCUCAUGUGCCCCUC-
CGCCUGGAUCAC 
Seq16 AAAAAACUCGAACAUUUC-
CACUAACCAACCAUA-
CUAAAGCACCGC 
Seq2_12_35 AAAAAUUAACCAUCAGAU-
CAUGGCCCCUGCCCUCU-
CAAGCACCAC 
Seq15_12_35 AAAAAGAG-
GACGAUGCCGACUAGCCU-
CAUCAGCUCAUGUCCCCCUC 
Seq15_15_38 AAAAAGAGGACGAUGCG-
GAUUAGCCUCAUCAGCU-
CAUGUGCCGCUC 
Table 1. The five studied sequences, from (Hu et al., 
2015). Seq1 is an Ang2-specific aptamer, Seq16 is an 
Ang1-specific aptamer, the other three are Ang2-
mutated sequences.  
 
In Table 2 are listed the percentage/number of 
Hair and Belt configurations took into account 
in this paper. 
 
Name  Hair  Belt   
 %     n %     n Total n 
Seq1 24 43 76 134 177 
Seq16 44 103 56 133 236 
Seq2_12_35 32 102 68 219 321 
Seq15_12_35 35 55 65 102 157 
Seq15_15_38 29 26 71 63 89 
Table 2.  The percentage/number (n) of the studied 
Hair and Belt configurations. 
 
In the next, the results will be presented on vio-
lin plots; outliers, i.e. values more than 1.5 
times the interquartile range, or approximately 3 
standard deviations in a Gaussian distribution, 
have been dropped out.  In general, we pay 
careful attention to the outliers, because they 
can signal skewed distributions rather than a 
statistical error in a unimodal and symmetric 
distribution. The RC value best representing 
our networks was 11.3 Å; this value was suffi-
ciently large to have a connected network, but 
not so large to hide the node peculiarities (Al-
finito et al. 2017). 
Hereafter, the terms “network” and “graph” 
have to be considered synonyms.  
 
Graph representation 
 
In Figure 2 two typical networks for Hair and 
Belt conformers are drawn. Hair conformers 
seem to describe “golf-club” networks, in 
which aptamer is positioned above the Ang2 
(dark grey zone), while Belt conformers de-
scribe a circular structure above the network 
protein (dark cyan zone).  In both conformers, 
the average number of links is constant in all 
the sequences, reporting a value of 6150, for RC 
= 11.3 Å. 
 
 
Figure 2. Networks for Hair (a) and Belt (b) conform-
er. The Hair conformer seems to describe a “golf-club” 
network, in which aptamer is positioned above the Ang2 
(dark grey zone), while the Belt conformer describes a 
circular structure above the protein (dark cyan zone). 
 
Assortativity 
From Figure 3a, it is evident that the assorta-
tivity coefficient assumes a positive value and 
significantly greater than zero; it varies in the 
range [0.51- 0.55], showing a very slight in-
crease, as a general trend, in the Hair conform-
ers. Even if seemingly a distinct discrimination 
does not exist between the two conformations, 
Figure 3a clearly shows how the shape of the 
distribution for natural sequences (Seq1 and 
Seq16) is much more compact (Gaussian) than 
the mutated ones. These last sequences exhibit 
a less regular behavior, especially Seq15_12_35 
and Seq15_15_38.  
 
Hierarchy 
From the findings, it is possible to state that the 
rank of the network is very high for low degree 
value; thus, even increasing the rank, the degree 
decreases exponentially. The average values are 
almost constant for all the sequences, in both 
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the conformations. Therefore, it seems that it is 
not possible to discriminate. Figure 3b shows 
this too weak fluctuation of hierarchy, even if 
Belt conformations linked to the natural se-
quences exhibit a more homogeneous shape of 
the distribution. Under certain aspects, this 
could be considered as an indicator of the quali-
ty of the in silico realization of the aptamer-
Ang2 complex. 
 
 
Figure 3. Assortativity (a) and hierarchy (b) coefficient 
distribution for the five aptamer-Ang2 complexes, gray 
for Hair and cyan for Belt. 
 
Diameter 
The diameter, intended as the maximum dis-
tance between two points of the network, could 
provide important information to discriminate 
between the two conformers. In particular, it 
could be hypothesized that the Belt conformers 
should have the highest values, since the ap-
tamer, positioning itself around the protein, 
should increase the diameter of the network.  
However, this difference is not so evident (Fig-
ure 4a); the diameter turns out to be compara-
ble for all the sequences, expressing for all the 
networks a small-world behaviour (Watts and 
Strogatz 1999). 
 
Average length of the path  
Figure 4b shows that the average path length in 
the Hair configurations is greater than the Belt 
ones, as expected. In fact, when aptamer sur-
rounds protein, it is closer than when it is posi-
tioned above, namely in the Hair configuration. 
 
 
Figure 4. Diameter (a) and average length of the path 
(b) distribution for the five aptamer-Ang2 complexes, 
gray for Hair and cyan for Belt. 
 
 
Average clustering coefficient  
The average clustering coefficient is calculated 
as the average of all the coefficients of local 
clustering. Figure 5a shows that the Hair con-
figurations values are higher than the Belt ones. 
In particular, the shape of the distribution 
points out appreciable variations for the mutant 
(Seq2_12_35, Seq15_12_35, and Seq15_15_38) 
compared to the natural (Seq1 and Seq16) se-
quences. 
 
Maximum eigenvalue 
The maximum eigenvalue of the Laplacian ma-
trix was calculated according to the Perron-
Fröbenius theorem. This eigenvalue has an as-
sociated eigenvector with no negative values for 
not oriented graphs, as those we examined. 
This is useful for centrality measures, in a sense 
that network with high centrality has many 
nodes with short contacts. This happens, as ex-
pected, for Belt conformers, as shown in Figure 
5b. 
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 Figure 5.  Average clustering coefficient (a) and maxi-
mum eigenvalue (b) distribution for the five aptamer-
Ang2 complexes, gray for Hair and cyan for Belt. 
 
 
Conclusions 
 
Graph theory has been extensively applied in 
several fields of research, but applications to 
aptamer-protein complexes are still pioneering. 
The reasons reside in the fact that few struc-
tures are experimentally resolved, the results 
obtained by the application of the theory can-
not be compared with a general, well-
established model. 
In (Cataldo et al. 2019) it has been observed 
that in silico aptamer-Angiopoietin complexes 
were arranged in two main conformers: Hair 
and Belt. Here, we study the same structures by 
using the concepts of graph theory with the aim 
to assess if the interpretation of networks could 
anticipate some characteristics, typical of those 
configurations. 
From the graphs, differences between the 
two types of conformers are very clearly de-
duced, starting from the visual representations. 
As for other topological parameters, the as-
sortativity and hierarchy coefficients did not 
highlight a clear difference, but the shape of the 
distribution clearly reflects two different behav-
iours, able in appreciably discriminating the 
conformations. Discrimination becomes more 
evident in the average length of the path, the 
clustering coefficient and the maximum value 
of the eigenvalues of the adjacency matrix. In 
general, consistent differences are highlighted in 
the shape of the distribution for all the parame-
ters, this is particularly true in the aptamer-
Angiopoietin complexes derived from natural 
sequences (Seq1 and Seq16), compared to the 
mutated ones. 
For the sake of completeness, another type of 
conformer (Figure 6) has been noted during the 
analysis of the networks. It is different from 
Hair or Belt and further investigations are 
needed in this regard. 
 
 
Figure 6. Examples of conformers, different from Hair 
or Belt configurations. 
 
The achievement of these results can be con-
sidered a merit of the application of graph the-
ory and, conversely, a precise indication of the 
fact that other efforts are required to perfect 
molecular simulation software, so that a de-
scription as close as possible to the real struc-
ture of the complexes can be reached.  
We consider the proposed procedure effective 
in the screening process of the outcomes of dif-
ferent computational software, thus, it can be 
applied as a useful tool for increasing chances 
of success in designing high-specificity biosen-
sors. 
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Abstract 
A wide spectrum of diseases or conditions (genetically based or acquired), in the presence of triggering elements, 
can lead to arrhythmic events, having sudden death as a common result. The substrate of fatal arrhythmia de-
pends on age: over 35 years old it is mainly represented by the instability of coronary heart disease. Up to 35 
years of age, the substrate consists mainly of electrical or structural alterations of the heart of a genetic nature the 
main of which are i) idiopathic hypertrophic cardiomyopathy ii) arrhythmogenic cardiomyopathy of the right 
ventricle iii) congenital syndrome of long QT iv) congenital syndrome of short QT; 
v) Brugada syndrome. Each of these proarrhythmic genetic conditions has the prerogative of being able to be 
highlighted by an electrocardiogram: a simple and economical gesture that can lead directly to an important diag-
nosis, or at least make it suspected, addressing the subsequent evaluations. Formulating a diagnosis of this kind 
can minimize the risk of sudden death, through careful use of lifestyle advice, drugs, devices, procedures. It has 
been scientifically proved that identifying genetic conditions at risk of malignant arrhythmias in the athlete leads 
to a dramatic reduction in the risk of sudden death: on this basis, an electrocardiographic screening has become 
peremptory in many countries in order to be able to perform competitive sports (in Italy, for some years, also to 
be able to carry out non-competitive sports). Electrocardiographic screening should be considered for the entire 
youth population, regardless of participation in an organized sports activity program, as this can potentially mean 
saving young lives from sudden death. 
 
 
Keywords: sudden death; electrocardiogram; hypertrophic cardiomyopathy; congenital long QT syndrome;  
Brugada's syndrome 
 
 
Introduction 
 
Sudden cardiac death (SCD) in young adults 
(<35 years) is an emotionally staggering event, 
not only for the victim’s family but also for the 
community. Although the precise incidence of 
this catastrophic event is not exactly known 
around the world, in the USA it ranges between 
0.8 and 8 deaths per 100,000/year (Vetter 2014, 
688–97). As everywhere, even in Salento the 
SCD in young people is not a negligible event: 
the case of Lorenzo T., a 19-year-old male vic-
tim of SCD  just as he had come out of a disco  
after a happy evening with friends, in which the 
autopsy examination revealed the presence of 
hypertrophic cardiomyopathy  is perhaps the 
most sensational case, but it is only the tip of 
the iceberg. SCD is not a single disease, but the 
outcome of a wide spectrum of diseases or 
conditions in which a substrate (genetic or ac-
quired) interacts with a series of physiological 
or pathophysiological factors (acute ischemia, 
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reperfusion, hyperadrenergic status, etc.) that 
modulate its arrhythmic propensity, in the pres-
ence of a triggering factor (Costantini 2019). 
This triad can lead to an intraventricular reentry 
(single or multiple), or result in post-potential 
triggered electrical activity, with the risk, in 
both cases, of producing a fatal arrhythmic ac-
cident. Such a paradigmatic sequence justifies 
most of the cases of sudden death, but the sub-
strate is age-dependent: up to 35 years of age, 
the prevailing substrate is represented by elec-
trical or structural alterations of the heart of ge-
netic origin; above the age of 35, it is mostly 
represented by the consequences of a coronary 
heart disease (Costantini 2019). An early recog-
nition of these arrhythmogenic conditions in 
the juvenile population could markedly reduce 
the risk of sudden death, as already evidenced 
in young athlete (Vetter 2014, 688–97).  Below 
we will consider some of the characteristics re-
lated to the main hereditary proarrhythmic 
conditions. 
 
Hypertrophic cardiomyopathy 
 
It is a hereditary disease of the heart muscle, 
caused by mutations in the genes that encode 
sarcomere proteins (Pasquale et al. 2012, 10–
17). The genetic abnormality results in a par-
ticular anatomical situation (myocardial hyper-
trophy, often asymmetric, sometimes mon-
strous; structural disorganization of the myofi-
brils, "disarray"; fibrosis) which determines a 
rather wide spectrum of functional and clinical 
alterations ranging from total asymptomaticity 
to myocardial ischemia, diastolic dysfunction, 
obstruction of left ventricular efflux, life-
threatening arrhythmias and  sudden death 
(Spirito, Quarta and Autore 2009, 1104–10). It 
is therefore a rather complex heart disease that 
has a high prevalence, estimated between 1/500 
and 1/1000. The disease often remains undiag-
nosed. The phenotypic aspects include left ven-
tricular hypertrophy, sometimes marked, often 
asymmetric, cavity of the left ventricle not di-
lated, conserved systolic function, dynamic ob-
struction in the left ventricular outflow tract (in 
20% of cases), electrocardiographic changes, 
arrhythmias, sudden death (Spirito, Quarta and 
Autore 2009, 1104–10). The clinical course is 
extremely variable. Many patients have normal 
life spans, remaining completely asymptomatic. 
Others develop heart failure, others die sud-
denly, often at a young age and without any 
warning symptoms. Massive hypertrophy and 
disarray, together with fibrosis, constitute a fa-
vorable substrate for several arrhythmogenic 
mechanisms that can be favored by intercurrent 
modulating factors (autonomous nerve factors, 
emotional stress, acute myocardial ischemia, 
electrolyte disturbances, drugs), with arrhyth-
mias of various kinds, up to malignant ventricu-
lar forms.  Usually the disease is suspected for 
the presence of a pathological ECG,  with QRS 
alterations (often Q of necrotic aspect) and 
ventricular repolarization alterations  (negative 
T waves in anteriorior and/or  lateral and/or  
inferior  leads, figure1) , during a screening for 
sports activity or for family history of hypertro-
phic cardiomyopathy or less often for symp-
toms (Migliore et al. 2012, 529–38). The diag-
nosis is then confirmed by an echocardiogram. 
In a minority of cases, a clearly pathological 
ECG is not followed by the presence of left 
ventricular hypertrophy at the echocardiogram 
(Spirito, Quarta and Autore 2009, 1104–10). In 
such cases (phenotypically incomplete) cardiac 
nuclear magnetic resonance may help. 
 
 
Figure 1. Classical ECG pattern in HCM 
 
Arrhythmogenic Right Ventricular Cardio-
myopathy/ Dysplasia (ARVD) 
 
ARVD is a progressive disease of myocardial 
tissue clinically characterized by ventricular ar-
rhythmias, heart failure, sudden death 
(Domenico Corrado and Thiene 2006, 1634–
37). The distinctive character of the disease is 
the replacement of cardiomyocytes with fibro-
adipose tissue with a particular structural and 
functional involvement of the right ventricle 
(but in more than half of the patients the left 
ventricle is also affected). In most cases it is a 
genetically determined inherited disorder with 
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autosomal dominant transmission caused by 
mutations in the genes encoding desmosomal 
proteins, plakoglobin, desmoplakina, plakofil-
ina-2, desmoglein-2 and desmocollin-2. The 
disease has a variable prevalence from 1/1000 
to 1/5000 subjects in the general population 
and represents one of the main causes of sud-
den death in athletes and young people. Clinical 
manifestations generally develop between the 
second and fourth decades of life and include 
palpitations, syncope, ventricular tachycardia, 
sudden death (D. Corrado et al. 2009, 1097–
1103). The morphological progression of the 
disease can lead to right or biventricular heart 
failure. In basal  ECG, abnormalities of various 
kinds are found in about 90% of cases, very 
useful both for making the diagnosis and for 
establishing the prognosis and the evolution of 
the disease (figure 2): P wave accentuated;  pro-
longed PR tract; extension of the QRS dura-
tion; right bundle branch block of varying de-
grees; presence of epsilon wave (small positive 
low voltage deflection in the final part of the 
QRS or at the beginning of the ST segment in 
the right precordials: it expresses delayed activa-
tion of portions of the right ventricle and corre-
sponds to the late recordable potentials with 
high resolution electrocardiography); negative T 
waves in the right precordial leads (D. Corrado 
et al. 2009, 1097–1103). The arrhythmic spec-
trum of the disease is variegated and ranges 
from ventricular, isolated or repetitive extrasys-
toles, sustained ventricular tachycardia, and 
ventricular fibrillation.     
 
 
Figure 2. ECG of a subject with ARVD. Note the 
altered QRS, with right bundle branch block and prob-
able epsilon wave in V1 
 
Brugada's syndrome 
 
It is a genetically based electrical disease that 
involves risk of sudden death (Brugada and 
Brugada 1992, 1391–96). The incidence of the 
condition is currently estimated around 5 cases 
per 10.000 (Antzelevitch et al. 2005, 429–40). 
Affected subjects have a defect in the gene that 
codes for the sodium channel:  its function is   
depressed, leading to a transmural electrical in-
homogeneity, which creates a voltage gradient 
between the epicardium and the endocardium.  
It is likely that the voltage gradient is due to an 
early repolarization in epicardial cells of the 
right ventricle: the genetic defect produces in 
these cells a deficit of sodium current during 
the phase 1 of the action potential, altering the 
balance between depolarizing and repolarizing 
forces, creating a strong predominance of the 
potassium repolarizing current (Ito). Since the 
subendocardial cells have a lower concentration 
of Ito channels, a clear difference in silhouette 
of the action potential between endocardium 
and epicardium takes place, producing voltage 
gradient, which favors the possibility of re-entry 
triggering in phase 2. 
Classically, three different types of Brugada’s 
patterns are derived from the basic ECG (Priori 
and Cerrone 2009, 1086–96): 
•Type 1: in this case it is evident a convex ele-
vation of the ST tract (coved type) of at least 
2 mm with evident J wave and negative T 
wave in V1 and / or V2 (figure 3); 
•Type 2: the ECG shows at V1 and / or V2 
an elevation of the point J of at least 2 mm 
and an elevation of the ST segment of at least 
1 mm and a positive or diphasic T wave; 
•Type3:  there is an elevation of the point J of 
less than 2 mm and a saddle back elevation of 
ST of less than 1 mm with a positive T wave 
in V1 and/or V2. 
 
Experts agree that only type 1 is diagnostic of 
syndrome (or pattern). Pattern 1, if not present 
in basal, can be disclosed by a pharmacological 
test, with flecainide or ajmaline, intravenously 
injected with great caution and under strict elec-
trocardiographic and clinical control. Some-
times the typical ECG alteration in right pre-
cordial derivations is absent or just mentioned 
but appears or becomes more striking if the 
electrodes of the precordial right V1 and V2 are 
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moved higher (Priori and Cerrone 2009, 1086–
96). The typical basal ECG aspect of the syn-
drome is not fixed, but it can suffer fluctuations 
(important to record ECG during fever). The 
sudden death is caused by a polymorphic ven-
tricular arrhythmia and occurs especially during 
sleep or rest. Fever can be a factor of risk for 
malignant ventricular arrhythmias in affected 
subjects. The transmission of the condition is 
autosomal dominant with age penetrance and 
sex-dependent: clinical manifestations are more 
common in adult subjects and are 8 times more 
frequent in men than women. Ventricular fibril-
lation occurs at an average age of 41 ± 10 years, 
but can appear at any age, usually at rest or dur-
ing sleep. Temperature, abuse of alcoholic bev-
erages and large meals can reveal the ST seg-
ment elevation, with type 1 –appearance and 
predispose to the onset of malignant arrhyth-
mias. Pharmacological treatments with drugs 
that produce an accentuation of the defect of 
the ion channels (such as sodium-blockers an-
tiarrhythmics), may represent a major risk in af-
fected patients (Priori and Cerrone 2009, 1086–
96). 
 
 
Figure 3. Classical Brugada’s-Type 1 pattern 
 
Congenital long QT syndrome (LQTS) 
 
Genetically transmitted electrical disease, char-
acterized by prolonged QT and high risk of ma-
lignant ventricular arrhythmias (torsade de 
pointes, which sometimes degenerates into ven-
tricular fibrillation). Most arrhythmias arise in 
conditions of mental or physical stress. The 
beta-blocker therapy markedly reduces the mor-
tality of this condition and therefore every ef-
fort is necessary for the diagnosis to be made in 
the affected persons (Schwartz, Periti and Mal-
liani 1975, 378–90). The genes involved are 
numerous, and hence the multiplicity of the va-
rieties already described , but the most frequent 
forms of LQTS are the first three varieties: the 
first two (LQTS 1 and LQTS 2)  derive from a 
genetic defect of potassium channels with loss 
of function; variety 3 (LQTS 3)  derives from a 
genetic defect of the sodium channel, with a 
gain in function (Schwartz and Crotti 2009, 
1071–78). 
PJ Schwartz proposed a very useful risk score 
for the cardiologist in diagnostic judgment (PJS 
score), which is based on the following ele-
ments: ECG and documented arrhythmias, 
medical history and family history (Schwartz 
and Crotti 2009, 1071–78).  A PJS score ≥3.5 
can be associated with a higher probability of 
disease presence. With a score between 1 to 3, 
the probability that the disease is present in the 
patient is intermediate, while a PJS score ≤1 
can be associated with a low probability of 
LQTS.  Often, a careful analysis of the ECG 
allows to differentiate between the various 
types of LQTS (at least among the main ones), 
therefore it is sometime possible to identify the 
genotype with a simple electrocardiogram 
(Schwartz and Crotti 2009, 1071–78). Thus, in 
type 1 a "homogeneous" elongation of the QT 
is classical, with evidence of very broad base T 
waves. In type 2 the presence of "notched" T in 
many derivations is characteristic (figure 4). In 
type 3 (the one that originates from an exalted 
sodium current and that responds less to beta-
blocking therapy) the late manifestation of the 
T wave is characteristic: it occurs late, after a 
long ST segment often quite isoelectric. The ex-
istence of gene-specific triggers of arrhythmic 
events, different in the various forms of con-
genital long QT, is demonstrated (Schwartz and 
Crotti 2009, 1071–78). Thus, subjects with 
LQT 1 are at higher risk of arrhythmias during 
exercise (especially during swimming). Subjects 
with LQT 2 are very sensitive to loud noises, 
especially during sleep. Subjects with LQT 3 are 
more at risk during sleep or rest. 
Marcello Costantini, Massimo Trianni, Giuseppina De Benedittis, Cristina Tritto, Lorenzo Costantini, Luana Conte, Marco Greco, Michele Maffia, Michele De Benedetto 
 
39 
 
Figure 4. Type 2 congenital long QT syndrome 
Short QT syndrome (SQTS) 
 
Short QT syndrome is a genetically transmitted 
disease represented by the association between 
a very short QT to the ECG together with a 
propensity to develop atrial and ventricular 
tachyarrhythmias, in the absence of cardiac 
structural alterations (Gussak et al. 2000, 99–
102). The mainstay of diagnosis of short QT 
syndrome is the 12-lead ECG: the diagnosis is 
made when duration of corrected QT is ≤340 
ms (figure 5).  Other features that may be seen 
on the ECG in short QT syndrome include tall, 
peaked T-waves and PR segment depression 
(Giustetto et al. 2006, 2440–47). The prevalence 
of SQTS in the population is likely around 
0,1%. The disease   appears to be associated 
with high lethality in all age groups, including 
children in early life. Criteria scientifically vali-
dated as independent risk factors for cardiac ar-
rest are lacking, and therefore remains to be 
clearly defined what is the optimal primary pre-
vention strategy in asymptomatic patients with 
this condition. No data are available to stratify 
the arrhythmic risk during competitive physical 
activity. Some reports show that quinidine is ef-
fective in prolonging the QTc interval and is 
likely to reduce arrhythmic events in these pa-
tients.    
 
 
 
Figure 5. ECG of a subject with short QT and atrial 
fibrillation. Atrial arrhythmias are common in short 
QT syndrome. 
 
All the conditions considered above have the 
prerogative of being able to be highlighted with 
an electrocardiogram: a simple and inexpensive 
gesture can therefore lead directly to the diag-
nosis or can make it suspect.  Diagnostic as-
sessment can minimize the risk of fatal events, 
through appropriate use of behavioral advice, 
drugs, devices, procedures.  There is a scientific 
evidence that ECG screening identifies athletes 
who are harboring potentially serious arrhyth-
mic events and that this strategy strongly re-
duces the incidence of SCD in competitive ath-
lete (Domenico Corrado et al. 2003, 1959–63); 
for these reasons, ECG screening in athletes is 
endorsed by learned scientific and sporting or-
ganizations.  Why then is a similar approach not 
extended to the entire youth population regard-
less of participation in an organized sports ac-
tivity program?    Something is indeed forgot-
ten:  although intense exercise in individuals 
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harboring quiescent cardiac pathology leads a 3-
fold greater risk of SCD in elite athletes com-
pared with non athletes, the majority of SCD in 
the young affect the general population  be-
cause  a lower   incidence    acts   on a broader  
population (Domenico Corrado et al. 2003, 
1959–63).  In most countries, young people are 
not offered cardiac screening unless they are 
engaged in top-level competitions, but this is in 
contrast, both ethically and legally, with the 
fundamental principle of equality of all indi-
viduals. Perhaps, it is time to reflect on the 
ECG screening of the entire youth population, 
not only of the athletes. In the 1960s the World 
Health Organization (WHO) adopted scientific 
criteria for the evaluation of health screening 
programs (A.a.v.v. 1968, 318).  
According to these criteria, a screening program 
is justified if:  
1) the morbid condition to be identified 
is relevant from a public health point of view;  
2) there is a proven efficacy test for the 
early identification of the morbid condition, to 
allow early treatment;  
3) there are effective therapeutic meas-
ures for the morbid condition if diagnosed at an 
early stage;  
4) there is evidence that such therapies, 
if started in the presymptomatic phase, im-
proves the clinical course and the prognosis of 
the morbid condition.  
We believe that all these criteria are met by an 
electrocardiographic screening in youth age and 
that also the cost-effective ratio would be ad-
vantageous (Domenico Corrado et al. 2011).  
    But a few important issues arise: 
1) What about false negatives? Some congenital 
conditions at risk of sudden death are not ac-
companied by alterations in the basic electro-
cardiogram. Among these, we must mention 
the Catecholaminergic Polymorphic Ventricular 
Tachycardia, the congenital anomalies of coro-
nary origin, the aortopathies. It should also be 
considered that even in the ECG-evident proar-
rhythmic conditions the diagnosis can escape 
due to the dynamic character of the ECG-
changes, which may be elusive at the time of 
screening (Priori and Cerrone 2009, 1086–96; 
Schwartz and Crotti 2009, 1071–78).  
 
2) What about false positives? The ECG is dy-
namic by nature: up to 7 years, T waves in the 
right precordials are physiologically negative; 
successively, they gradually positivize. When the 
T waves remain negative beyond V1 after the 
age of 14, is it necessary to question whether 
one is dealing with a juvenile pattern or ARVD 
(18).   Furthermore, regular and long-term in-
tensive exercise is associated with several elec-
trical manifestations that reflect enlarged car-
diac camber size and increase vagal tone 
(Chandra et al. 2014, 2028–34). To facilitate the 
interpretation of the ECG in athlete, the Euro-
pean Society of Cardiology has produced guide-
lines able to differentiate the normal ECG 
scheme belonging to the trained subject, from 
the one relative to a subject with an underlying 
heart disease, although a certain overlap can still 
be observed in some cases (Chandra et al. 2014, 
2028–34). 
 
    In addition to these, other issues of non-
negligible importance emerge, such as the 
amount of subjects considered positive at 
screening, who need further investigations or 
eventually therapeutic measures and follow-up , 
with relative costs and assumption of responsi-
bility by  the health system and operators. Last 
but not least, there is  a subtle question regard-
ing the psychological impact of screening: dis-
covering an arrhythmic  condition certainly has 
markedly positive aspects, but we should ask 
ourselves what psychological impact it could 
have on an asymptomatic individual and his 
family, learning from an unknown doctor that 
his heart is at risk of serious arrhythmias. 
 
In conclusions, prevention of SCD in young 
people, athletes and not, remains a high priority 
for the medical community. 
 We have the task of overcoming the difficulties 
and defining the most appropriate strategies to 
reach such an ambitious goal. 
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Intrapartum ultrasound during prolonged second stage of labor: a diagnostic tool suggested 
for operative delivery to reduce complications. 
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Abstract 
Diagnosis and management of prolonged second stage of labor and its complications is difficult and often poses 
a dilemma to the treating obstetrician regarding timing and type of intervention. Nowadays, the diagnosis of dys-
tocic prolonged second stage of labor is largely based on digital evaluation of cervical dilatation and fetal head 
station and position, resulting inaccurate and subjective. Moreover, the problem of timing of delivery for nullipa-
ra during dystocic labor and labor analgesia is clinically unsolved, as well as questioned since many years. Thus, 
labor management is largely based upon clinical and not instrumental findings. Women in dystocic labor require, 
often, operative delivery, after many hours of pain during labor. Accurate assessment of fetal head position and 
station is crucial in clinical decision-making during the second stage of labor and the fetal station was misinter-
preted as lower than it really was in 15–22% of cases. Misdiagnosis or failure to correctly identify the fetal head 
position and station is one of the causes of failed instrumental delivery and subsequently of higher rate of neona-
tal morbidity. Intrapartum ultrasound also distinguishes patients destined for spontaneous vaginal delivery from 
those to submit to operative delivery. The intrapartum US is an adjunctive tool for labor ward obstetricians in 
the management of prolonged second stage and dystocia. It is a more objective and reliable tool than digital ex-
amination, and may give the obstetrician a more accurate perspective before making crucial clinical decisions re-
garding the chances of a successful vaginal delivery, and may lower the rate of failed instrumental delivery and its 
associated morbidity. 
 
Keywords: Intrapartum ultrasound, prolonged second stage of labor, operative delivery, obstructed labor, dysto-
cia, vacuum extractor, cesarean section. 
 
Introduction 
 
The philosophy of labor is based on two im-
portant queries: when and how to deliver. The 
answer to these two questions seems apparently 
simple but, on the contrary, it is extremely 
complex and abstruse. On the one hand there is 
the pregnant, full of anxiety and uncertainty 
about what will happen, on the other there is 
the fetus that must pass through the uterus that 
pushes it, the birth canal. In between there are 
dozens and dozens of variables and risk factors, 
for a sudden and unexpected modification of 
labor, while staying cognizant of monitoring 
safety and preventing harm. 
The second stage of labor begins, basing on 
FIGO guidelines, from full dilatation of the 
cervix up to the birth of the singleton baby or 
the last baby in a multiple pregnancy (FIGO 
Safe Motherhood and Newborn Health 
(SMNH) Committee 2012, 111–16). At the start 
of the second stage, the fetal presenting part 
may or may not be fully engaged (meaning that 
the widest diameter has passed through the pel-
vic brim), and the woman may or may not have 
the urge to push (FIGO Safe Motherhood and 
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Newborn Health (SMNH) Committee 2012, 
111–16) 
Second stage may get unduly prolonged be-
cause of cephalopelvic disproportion (CPD), 
abnormal fetal position, and poor expulsive ef-
forts resulting from conduction analgesia, seda-
tion or maternal exhaustion. Many clinical fac-
tors can influence the progress of the second 
stage of labor.  
These factors include maternal characteristics, 
such as age, parity, the size and shape of the 
pelvis, height and weight, uterine contractile 
forces, soft tissue resistance, expulsion effort, as 
well as presence of medical/obstetric condi-
tions, including hypertensive disorders or 
pregestational/gestational diabetes mellitus. Fe-
tal characteristics include birth weight, fetal oc-
ciput position/degree of flexion, and station at 
complete cervical dilation (Cheng and Caughey 
2017, 547–66) 
Prolonged second stage of labor is generally as-
sociated with several maternal and perinatal 
complications, including: increased operative 
vaginal delivery (OVD), cesarean section (CS), 
third- and fourth-degree perineal tear, cervical 
injury (with increased risk of preterm delivery in 
the subsequent pregnancy), post-partum hem-
orrhage (PPH) and chorioamnionitis. Neonatal 
complications include low 5-minute APGAR 
score, admission to the Neonatal Intensive Care 
Unit, birth trauma and birth depression (Cheng 
and Caughey 2017, 547–66; FIGO Safe Moth-
erhood and Newborn Health (SMNH) Com-
mittee 2012, 111–16) 
In management of a second stage of labor, 
there is a large evidence that digital obstetric 
examination does not provide an accurate as-
sessment of the descend and position of the fe-
tal head during the first and the second stage of 
labor (Malvasi et al. 2014, 520–26).  
Investigations showed that digital obstetric ex-
amination during labor and delivery frequently 
fails to identify the correct fetal position in a 
high proportion of cases and ultrasonography 
in labor may play an important role in labor and 
delivery management (Sherer et al. 2002, 258–
63; Sherer et al. 2002, 264–68) 
Recent studies using intrapartum ultrasound 
(IU) have described objective measures of pro-
gression of the fetal head during labor, with a 
reduced error in diagnosis of fetal head position 
and progression (Malvasi et al. 2016, 2408–13) 
Prolonged second stage may be managed by 
oxytocin augmentation, instrumental delivery or 
caesarean section and the safe use of vacuum 
extractor (VE) and forceps during OVD as-
sumed the use of IU for the correct determina-
tion of the fetal head position and appropriate 
application of the instrument (Gustapane, Mal-
vasi and Tinelli 2018, 540–41).  
The use of IU is of fundamental importance for 
a safe OVD and can help in the prediction of 
whether a vaginal delivery would be successful, 
since scientific evidences suggested that IU may 
play an important role in the prediction of the 
time of onset and the progress of labor (Chor, 
Poon and Leung 2019, 31–37; Barak et al. 2018, 
9–14; Choi et al. 2016, 3988–92) 
The modern obstetric management of second 
stage is an ongoing challenge to reduce rates of 
emergency cesarean deliveries and to avoid ad-
verse maternal and neonatal outcomes, since 
spontaneous parts are reduced and maternal 
and fetal complications are increased. 
Thus, we performed a literature analysis to as-
sess the impact of IU on management of pro-
longed second stage of labor, to assess its utility 
for operative delivery and if it can reduce com-
plications. 
 
Literature analysis 
 
The safe balance between maternal and neona-
tal benefits and risks during the prolonged sec-
ond stage of labor has been hindered by a lack 
of high-quality, prospective studies. The length 
of the second stage of labor was primarily de-
fined as the duration between complete cervical 
dilation and delivery of the fetus. According to 
American College of Obstetricians and Gyne-
cologists (ACOG) Practice Bulletin No. 49 on 
Dystocia and Augmentation of Labor, a pro-
longed second stage was defined as more than 2 
hours without epidural or 3 hours with epidural 
analgesia in nulliparous women, and 1 hour 
without, or 2 hours with epidural analgesia for 
multiparous women (American College of Ob-
stetrics and Gynecology Committee on Practice 
Bulletins-Obstetrics 2003, 1445–54) The addi-
tional hour allotted for labor with epidural an-
esthesia appeared to be based on the mean ef-
fect of epidural (Albers 1999, 114–19; Albers, 
Schiff and Gorwoda 1996, 355–59) 
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Subsequently, there were other literature data 
about the duration of the second stage of labor; 
recent recommendations often include longer 
durations in some cases, that is, that manage-
ment is individualized depending on progress 
of labor, epidural analgesia, fetal position and 
interventions (Cheng and Caughey 2017, 547–
66) 
An obstetric care consensus in 2014, on the 
safe prevention of primary CS, the ACOG and 
the Society for Maternal Fetal Medicine 
(SMFM) allow an additional 1 hour of extended 
pushing in the second stage of labor for nullipa-
rous and multiparous women before diagnosing 
second-stage arrest (Caughey et al. 2014, 179–
93)  
The extended second-stage labor represents a 
promising approach for balancing maternal and 
fetal risks, while working to reduce the rate of 
primary CS; nevertheless, the literature data are 
not yet sufficient to demonstrate the benefit of 
reducing CSs compared to maternal and fetal 
complications that may arise after a prolonged 
second stage of labor. 
We searched on PubMed/Medline, Scopus, 
Google Scholar, EMBASE, the Cochrane Da-
tabase, and a previous review the following key 
words: prolonged second stage of labor, intra-
partum ultrasound, dystocia, operative delivery, 
vacuum extractor, cesarean sections and com-
plications, to identify relevant articles published 
from 2000 and 2019 and to find the conclu-
sions to our queries.  
 
Intrapartum ultrasound in labor 
 
The literature analysis has amply demonstrated 
that, in the case of prolonged labor, the IU is 
much more reliable than the vaginal visit in the 
obstetric diagnosis of situation, position and fe-
tal progression. 
Studies largely demonstrated the major diagnos-
tic accuracy of IU to diagnose, during labor, the 
fetal head position (Sherer et al. 2002, 258–63; 
Sherer et al. 2002, 264–68), station (Dupuis et 
al. 2005, 193–97) and internal rotation (Ghi et 
al. 2009, 331–36; Malvasi et al. 2016, 2408–13) 
in the maternal pelvis, in comparison of tradi-
tional digital vaginal examination. 
Similarly, different trials report the superior di-
agnostic value of IU in the malpositions (Bel-
lussi et al. 2017, 633–41) and malrotations, 
(Simkin 2010, 61–71) during dystocic labor and 
delivery, especially in Occiput Posterior Posi-
tion (OPP) (Bellussi et al. 2017, 633–41) and 
asynclitism (Simkin 2010, 61–71). 
Moreover, the use of US did not have any nega-
tive impact on neonatal morbidity and mortali-
ty, basing on literature data. 
 
Intrapartum ultrasound in prolonged sec-
ond stage of labor 
 
Abnormal descent pattern leads to prolongation 
of the second stage of labor. This abnormal de-
scent is of two types: protracted descent and 
arrest of descent. Protracted descent is defined 
as descent of presenting part by less than 2cm 
per hour for multiparous women, and less than 
1cm per hour for primiparous women. The ar-
rest of descent is defined as no descent of the 
presenting part for more than one hour. Both 
may be an indicator of obstructed labor that 
needs an accurate IU diagnosis and a prompt 
intervention by OVD or CS. Nevertheless, pro-
longed attempts at VE are associated with neo-
natal morbidity and maternal trauma, especially 
so if the procedure is unsuccessful and an ur-
gent CS is performed.  
Moreover, important potential complications 
arising in the prolonged second stage of labor 
are fetal hypoxia and acidemia leading to “birth 
asphyxia,” failure of the presenting part to ro-
tate or descend appropriately leading to ob-
structed labor, and worsening or new manifes-
tations of maternal hypertension leading to ec-
lampsia (Sandström et al. 2017, 236–42).  
Maternal complications after a prolonged sec-
ond stage of labor are: infections, urinary reten-
tion, hematomas or ruptured sutures, especially 
in the early postpartum period; pregnants with 
pre-existing cardiac disease or severe anemia 
may be at risk of heart failure during the pro-
longed second stage, owing to the additional 
circulatory demands of active pushing (Steph-
ansson et al. 2016, 608–16) 
When patients have a delay or prolongation of 
the second stage, a prompt and thorough clini-
cal assessment by IU should be recommended, 
to rule out full bladder, malposition or/and 
malpresentation of the fetal head, apart the in-
adequate uterine activity, poor pushing effort, 
all signs of obstructed labor. 
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Thus, the IU can accurately determine fetal 
head position, station and progression in deliv-
ery canal, during the second stage of labor, and 
it can be of great help in the management of 
prolonged second stage of labor. 
An urgent CS during prolonged second stage of 
labor, “especially for a deeply engaged head” 
can be a nightmare for all obstetricians, since it 
can lead complications including: bladder injury 
while opening up of abdomen, difficulty in de-
livery of head, lateral extension of the angle 
causing broad ligament hematoma, tear of low-
er uterine segment (LUS) & downward exten-
sion of scar that may involve bladder, difficulty 
in tracing retracted LUS after surgery for which 
one may take a stay suture earlier, accidental in-
cision over vagina, PPH, puerperal infection 
and later fistula formation and pelvic organ 
prolapse (POP). 
Delivery of a deeply impacted head may pose a 
problem even during caesarean section. 
 
Intrapartum ultrasound and operative de-
livery 
 
Generally, misdiagnosis or failure to correctly 
identify the fetal head position and station is 
one of the causes of failed instrumental delivery 
and subsequently of higher rate of neonatal 
morbidity (Ben-Haroush et al. 2007, 308.e1-
308.e5; Murphy et al. 2001, 1203–7; Hiraizumi 
et al. 2012, 280–83).  
The VE and forceps are useful tools for con-
duction of vaginal delivery in prolonged second 
stage, to shorten and reduce the effects of the 
second stage of labor on maternal/fetal condi-
tions. Literature data report a failure rate of 
4%–8% for instrumental delivery, especially 
among women with risk factors such as obesity, 
fetal occipital-posterior position, and mid-cavity 
delivery (Bhide et al. 2007, 541–45; Aiken et al. 
2014, 796–803; Murphy et al. 2001, 1203–7) 
The US has been suggested as a more objective 
and reliable tool than digital vaginal examina-
tion for assessing fetal head position and station 
as well as in predicting the success of labor 
(Ghi et al. 2018, 128–39)  
Barak et al (Barak et al. 2018, 9–14) evaluated 
the impact of IU on VE attempts. They 
demonstrated that among women who also had 
an intrapartum US as part of the clinical deci-
sion-making process, during the second stage of 
labor, there was a trend toward a lower rate of 
failed VE (although not reaching a statistical 
significance), with lower rate of CS, higher rate 
of vaginal deliveries, and without significant dif-
ferences in neonatal outcome. Authors reported 
also that in the “+US” group, the CS rate was 
lower than in the “no-US” group. 
In addition, Duckelmann et (Dückelmann et al. 
2012, 484–88) evaluated the impact of IU on 
decision making for VE application, in a cohort 
of women with a prolonged second stage of la-
bor; authors showed that by using intrapartum 
US, they were able to lower the CS rate without 
increasing maternal and neonatal morbidity. 
This study concluded that the use of intrapar-
tum US can also lower the rate of failed VE at-
tempts. 
Sainz et al (Sainz et al. 2016, 1348–52) evaluat-
ed the predictive capacity of intrapartum trans-
perineal ultrasound (ITU) in prolonged second 
stage of labor, to predict cases of failure in fetal 
extraction in operative deliveries by VE. They 
evaluated the following IU parameters: Angle 
of Progression (AoP), Progression Distance 
(PD) and head direction (HD). In the trans-
verse plane, midline angle (MLA) and head-
perineum distance (HPD) were assessed. The 
VEs were classified as easy (three or less vacu-
um pulls), difficult (more than three vacuum 
pulls) or impossible (delivery completed by ce-
sarean section or CS). In the results, authors 
observed that the presence of an AoP with 
pushing <105°, a PD <25 mm, a "head-down" 
direction and a >45° MLA are very unfavorable 
ITU parameters which can be used to identify 
cases of high risk of fetal extraction failure in 
vacuum-assisted deliveries. Thus, ITU can help 
differentiate easy (3 pulls or less), hard (more 
than 3 pulls), or impossible (CS was needed) 
VE trials and that it is possible to identify high 
risk cases for failed VE by using some TPUS 
parameters. 
Chan et al (Chan et al. 2019, 192–98) evaluated 
patients in prolonged second stage of labor, 
measuring the AoP by ITU before, indicating 
an instrumental delivery or CS. Authors con-
cluded that AoP predicted approximately 80% 
of successful OVD performed for prolonged 
second stage of labor. This study’ observation 
was not surprising given that the AoP is known 
to widen as the fetal head descends along the 
birth canal, suggesting that a lowered fetal head 
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position in the pelvis might have favored vagi-
nal delivery. The study also found that median 
AoP during contraction with pushing was 20°–
30° wider than median AoP at rest, which im-
plied the presence of fetal head descent with 
maternal pushing. 
Several studies have suggested that an AoP of 
120° was associated with successful vaginal de-
livery (Sainz et al. 2016, 1348–52; Chan et al. 
2019, 192–98; Barbera et al. 2009, 313–19; 
Kalache et al. 2009, 326–30; Sainz et al. 2015, 
2041–47) but other studies suggested that AoP 
cutoff values of 105°–145.5° were associated 
with difficult or failed instrumental delivery 
(Ghi et al. 2013, 430–35; Cuerva et al. 2014, 
687–92; Bultez et al. 2016, 86–91)  
 
Gilboa et al (Gilboa et al. 2015, 399–404) eval-
uated, in a prospective study, different so-
nographic methods for the prediction of the 
difficulty and the success of OVD in pregnants 
with prolonged second stage of delivery with 
cephalic presentation. The investigated parame-
ters were the following: head station, passage of 
the biparietal diameter (BPD) of the infrapubic 
line (IPL), percentage of head after the IPL, 
head circumference after IPL were all correlat-
ed with the difficulty of OVD. When the dis-
tance between the widest diameter of the head 
and the IPL is < 1.2 cm, there is a 90 % proba-
bility of success of OVD. When that distance is 
> 3.3 cm, there is 90 % probability of cesarean 
section. When the percentage of head beyond 
the IPL was > 54 %, there was 90 % probability 
of successful OVD. 
Authors concluded that ITU was useful in the 
prediction of the difficulty and the success of 
OVD. The higher the extent of head that 
passed the IPL, the less difficult the OVD and 
the greater the success rate of the OVD. 
Kahrs et al (Kahrs et al. 2017, 69.e1-69.e10) 
evaluated, in a prospective cohort investigation 
on 222 pregnants, if ultrasound measurements 
of fetal position and station can predict dura-
tion of VE, mode of delivery, and fetal out-
come in nulliparous women with prolonged 
second stage of labor. 
The duration of VE was shorter in women with 
HPD ≤ 25 mm (log rank test <0.01). The esti-
mated median duration in women with HPD ≤ 
25 mm was 6.0 (95% confidence interval, 5.2-
6.8) minutes vs 8.0 (95% confidence interval, 
7.1-8.9) minutes in women with HPD >25 mm. 
The HPD was associated with spontaneous de-
livery with area under the curve 83% (95% con-
fidence interval, 77-89%) and associated with 
CS with area under the curve 83% (95% confi-
dence interval, 74-92%). In women with HPD 
≤35 mm, 7/181 (3.9%) were delivered by CS vs 
9/41 (22.0%) in women with HPD >35 mm (P 
<.01). Ultrasound-assessed position was occi-
put anterior in 73%. Only 3/138 (2.2%) fetuses 
in occiput anterior position and HPD ≤35 mm 
vs 6/17 (35.3%) with non-occiput anterior po-
sition and HPD >35 mm was delivered by CS. 
Umbilical cord arterial pH <7.10 occurred in 
2/144 (1.4%) women with head-perineum dis-
tance ≤35 mm compared to 8/40 (20.0%) with 
HPD >35 mm (P < .01). They concluded that 
IU has the potential to predict labor outcome in 
women with prolonged second stage of labor. 
Zipori et al (Zipori et al. 2019, 191.e1-191.e7) 
recently changed their approach to labor dysto-
cia, as recommended by ACOG/SMFM 
(Caughey et al. 2014, 179–93), extending the 
length of prolonged second stage of labor; they 
significantly decreased the primary CS rate, in 
both nulliparous and multiparous women. 
However, this practice of extending the second 
stage of labor was associated with a small rise in 
OVD among nulliparous women, as well as 
with increases in other immediate maternal 
complications, specifically, higher rates of PPH 
and of third- or fourth-degree perineal lacera-
tions. In assessing the neonatal complications, 
they noticed a higher rate of low umbilical ar-
tery cord pH in period II, but the early neuro-
logical outcome did not change. Authors con-
cluded that in a prolonged second stage of la-
bor, a CS can be done in all cases of doubt in 
order to prevent failed OVD, but a reduced 
rate of failed VE/forceps will be accompanied 
by an increased emergent CS rate. Thus, the 
benefits of safe prevention of primary CS, by 
extending the duration allowed for the second 
stage of labor, must be weighed against the po-
tential adverse maternal and neonatal outcomes. 
Muraca et al (Muraca et al. 2017, E764–72) in-
vestigated the effect OVD at mid-pelvis to re-
duce the CS rate, trying to quantify severe peri-
natal and maternal morbidity and mortality as-
sociated with attempted mid-pelvic OVD on 
more of 180000 pregnants. Among women 
with dystocia and prolonged second stage of 
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labor, mid-pelvic OVD was associated with 
higher rates of severe perinatal morbidity and 
mortality compared with CSs, especially with 
higher rates of severe birth trauma. Rates of se-
vere maternal morbidity and mortality were not 
significantly different after OVD, although 
rates of obstetric trauma were higher. 
Authors concluded that mid-pelvic OVD was 
associated with higher rates of severe birth 
trauma and obstetric trauma, whereas overall 
rates of severe perinatal and maternal morbidity 
and mortality vary by indication and operative 
instruments. 
 
Conclusions 
 
During a prolonged second stage of labor, as-
sessments of the balance of risks and benefits 
between mid-pelvic OVD and CS have tended 
to favor the latter option in recent decades to 
reduce maternal neonatal complications (Sand-
ström et al. 2017, 236–42; Shmueli et al. 2017, 
886–89; Altman et al. 2015, 1209–15; Salman et 
al. 2017, 1145–50; Stephansson et al. 2016, 
608–16) and this has contributed to a rising rate 
of CS worldwide (Zizza et al. 2011, 161–73; 
Boerma et al. 2018, 1341–48)  
Diagnosing and managing of a prolonged sec-
ond stage of labor is challenging, and prolonged 
second stage diagnoses will affect 10% to 14% 
of nulliparous and 3% to 3.5% of multiparous 
women (Cheng and Caughey 2015, 227–40)  
Currently, the decision to perform OVD is tra-
ditionally based on subjective assessment by 
digital vaginal examination and clinical expertise 
and there is currently no method of objectively 
quantifying the likelihood of successful delivery.  
The routine uses of IU or ITU should be en-
couraged during labor and in delivery room 
since there is large scientific evidence that digi-
tal obstetric examination either for the determi-
nation of fetal head position during labor or in 
the descent of the head in the birth canal is not 
accurate and IU is effective and feasible for a 
correct diagnosis (Tinelli, Di Renzo and Malvasi 
2015, 310–11; Malvasi et al. 2015, 1890–94; 
Gustapane, Malvasi and Tinelli 2018, 540–41)  
Moreover, for the successful and safe use of 
OVD, the correct determination of the fetal 
head position and appropriate application of 
the instrument by IU or ITU can reduce also 
the medical legal liability for VE failure or ma-
ternal and neonatal complications (Malvasi et al. 
2018, 1108–9; Eggermont 2015, 87–95)  
In fact, the IU demonstrated, also in such case, 
its great utility and precision in indicate, indi-
rectly, the correct placement of the vacuum cup 
on the flexing point and placement of the for-
ceps blades parallel to the sagittal suture. 
Both features are associated with high success 
rate and reduction in maternal and fetal mor-
bidity, since OVD is an integral part of obstet-
ric care and is indicated for prolonged second 
stage of labor or fetal compromise or to short-
en the second stage of labor for maternal indi-
cations. 
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Abstract 
At the beginning, it was the French philosopher Michel Foucault who explicitly defined medicine as a matter of 
biopolitics, making evident the role that, in his opinion, medical knowledge assumed in certain strategies of pow-
er. Starting from this assumption, the bioeconomic paradigm has been embodied in a form of governmentality of 
human behaviors, where the individuals are first and foremost considered biological living units. The biopolitical 
and bio-economic paradigm must not be considered as a space of absence of power, but a place where power 
leads to obedience by activating alternative devices, acting on population wishes and needs. These dynamics have 
slowly modified and even subverted the relationship between doctor and patient, determining the default of the 
paternalistic relationship and the strengthening of defensive medicine. 
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Biopolitics and bioeconomy  
 
The French philosopher Michel Foucault, in 
the second half of the last century, proposed a 
fructuous reflection focused on the concepts of 
biopower and biopolitics, whose interpretation, 
however, is not univocal; it is useful, therefore, 
to consider, in the first instance, some mean-
ings that the terms "biopower" and 
"biopolitics" assume in the huge production of 
the author. 
In 1974, Foucault spoke for the first time about 
the concept of biopolitics during the confer-
ence held in Rio de Janeiro about " The birth of 
social medicine". On this occasion two funda-
mental data emerge: the first, concerning the 
connection between biopolitics and capitalism, 
able to determine the possibility of implement-
ing a control on individuals, not only by con-
sciousness and ideology, but also through the 
body. 
The second, because of the first, is the im-
portance that the body assumes as a biopolitical 
reality and medicine as a biopolitical strategy 
(Foucault, 1997, 222). 
The real focus of Foucaultian researches, how-
ever, is not the living body, but rather its consti-
tution as a scientific object, as the specific 
knowledge indispensable for the exercise of a 
certain power. For this reason, Foucault's atten-
tion is often turned to all the published and in-
edited scientific speeches on the body.  
The initial reference of biopolitics to the body 
and medicine changes and expands a couple of 
years later, when he explains how the life power 
has developed in two directions, one focused 
on the body-machine, the other on the body-
species. In the first case, it is an anatomical-
political of the human body. It is materialized 
through processes of discipline and supported 
by mechanisms of power, both focused on the 
body to strengthen it, but also to make it "doc-
ile" and to incorporate it into effective and eco-
nomical control systems. 
In the second case, Foucault speaks specifically 
of biopolitics of the population, as the set of 
interventions and regulatory controls that, since 
the mid XVIII century, have addressed the set 
of living bodies constituting the population. Al-
so, in this perspective, the binomial constituted 
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by knowledge and power assumes a fundamen-
tal role. The affirmation of specific fields of 
knowledge, which not only include medical 
knowledge, but also demography, statistics and 
political economy, determines the possibility of 
managing the dynamics concerning health, hy-
giene, food, sexuality and all the biological pro-
cesses shared by living beings, as birth, prolifer-
ation, mortality, etc. 
Foucault precise that until the XVIII century, 
such management of the bodies were per-
formed according to the directions mentioned 
above in a distinct way. Together they inaugu-
rated bio-power era, which the author considers 
as an essential element for the development of 
capitalism, because of the controlled introduc-
tion of the bodies in the production chain and 
the adaptation of population phenomena to 
economic processes (Foucault, 1978, 123-124). 
The State has therefore adopted an economic 
rationality, determining the state transposition 
of “oikonomia” (the administration of the 
house), making it as a specific mode of inter-
vention in the public sphere (Esposito, 2015, 
19-20). 
Biopower, moreover, has shifted attention to 
the concept of norm, which has also begun to 
make its way in the legal context. Although it 
does not replace the law (i.e. the legal norm 
connected to power in the classical sense), it 
has undoubtedly led the law to function as a 
norm. It can be deduced from the fact that the 
juridical institution has increasingly integrated 
itself with other apparatuses, having medical 
and administrative regulatory functions. Unlike 
the law, which differentiates individuals based 
on what they do, playing on the contraposition 
between lawful and unlawful and, consequently, 
prohibiting or condemning, the norm usually 
identifies and differentiates both individuals 
and populations based on what they are, focus-
ing on the normal-pathological duality. 
What is outlined is, finally, a new technology of 
power, which Foucault sees fully realized in the 
framework of the so-called liberal 
"governmentality". Because of the mentioned 
concepts, it appears not attributable to the sim-
ple juridical analysis of sovereignty. Moreover, 
biopower requires the contribution of the eco-
nomic dimension. The object of this 
governmentality is the sum of singular and col-
lective living beings, anatomical bodies and bio-
logical bodies. The political rationality is in 
some measure forced to treat “omnes et 
singulatim”, producing at the same time indi-
vidualizing and totalizing effects (Foucault, 
2001, 145-146). 
 
Normalization and medicalization 
 
In the medical field, the governmental pro-
cess called "medicalization of society", charac-
terized by "a generalized medical conscience", 
was implemented by the task of controlling ei-
ther individual life, through the identification 
and treatment of diseases, or collective life, in 
order to define and implement specific health 
parameters. (Sorrentino, 2008, 108). In this 
context also hygiene represents, besides medi-
cine, a specific field of knowledge within a 
structured regime of health of the populations. 
It was based on the analysis of the habitats (cit-
ies, districts and houses) and on the rates of 
morbidity and mortality of the inhabitants, jus-
tifying authoritarian medical interventions in all 
those places at risk for possible diseases and ep-
idemics (Foucault, 1997, 195-196). 
The importance of medicine, not only 
methodologically but also ontologically, in the 
constitution of human sciences has thus 
emerged. It was the possibility for the individu-
al to be, at the same time, subject and object of 
his own knowledge (Foucault, 2005, XVII). 
Until the middle of the twentieth century, 
however, the role of medicine connected to the 
problem of health, undoubtedly fundamental, 
was seen from an essentially nationalist per-
spective. It was particularly aimed at ensuring 
health, to preserve the national physical force, 
the workforce, production capacity and military 
strength. 
For this reason, Foucault considered 1942 a 
date with a strong symbolic value. In that year 
the Beveridge plan was drawn up, showing, un-
like what had happened in the past, that the 
phenomenon of the consolidation of medicine 
was connected for the first time to a right to 
health. In addition, even though it was made 
explicit in a world context in which paradoxical-
ly millions of human lives were suppressed, the 
Beveridge plan appeared essential for the or-
ganization of health after the end of World War 
II. It consolidated not only the right to life, but 
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a different right, more important and complex, 
represented by the right to health. 
With the Beveridge Plan, the State takes on 
the social task of taking charge of the health of 
the members of society, with a profoundly dif-
ferent meaning from what had happened up to 
then. This is a reversal point of view, because 
the health concern does not longer apply to the 
State itself and its priorities, but rather individu-
als. No longer the healthy individual at the ser-
vice of the State, but the State at the service of 
the healthy individual. Foucault specifies how a 
kind of body morality has been defined, which, 
in the 19th century, had focused on cleaning 
and hygiene practices as a guarantee of good 
health. On the contrary, starting from the 20th 
century, it even goes so far as to support the 
right to suspend work because of illness. Health 
and illness thus became a budget item of the 
State, falling within the government macroeco-
nomic sphere. The Beveridge plan ultimately 
outlines the idea that the risks, connected with 
health and the possible interruption of work, no 
longer concern individuals but the State, which 
must therefore bear them (148-149). It is pre-
cisely on the basis of this approach that the aim 
of politics takes the name of welfare, because 
the state of well-being is guaranteed to citizens, 
who commit themselves to the contractual 
conditions of a pact, where the sacrifice of 
work is exchanged for insurance guarantees on 
health and old age. In this perspective, the 
management of the economic crisis by the capi-
talist economy assumes the connotations of a 
policy of salvation and of almost religious ma-
trix. It is also highlighted by the etymology of 
the terms "healthy" and "safe", which, within 
the social reforms of the second post-war peri-
od, highlight the overlap between the religious 
value of salvation and the biological value of 
health (Esposito, 2015, 67). 
 
Crisis of modern medicine: a game of rela-
tional asymmetries 
 
For Foucault, from the time of Constantine, 
many governments, including European ones 
up to the 18th century, have distinguished 
themselves for their theocratic role, character-
ized by pursuing the salvation of souls as their 
main objective; this role, however, has finally 
given way to a somatocracy, in which the main 
objective of State intervention is the care of the 
body, physical health, the relationship between 
health and disease (Foucault, 1997, 205). 
What Foucault reflects further on, however, is 
the crisis that is evident in current medicine, at-
tributable to the distance that would exist be-
tween scientific and effectiveness of medicine. 
In short, the possible negative effects of medi-
cine, including the risk of death, have been rep-
resented as a partial consequence of the igno-
rance of the doctor or of medicine itself, so, the 
harmfulness was proportional to its non-
scientific nature. At the beginning of the 20th 
century, however, the harmfulness of medicine 
was linked to its knowledge, to its being a sci-
ence (206). 
The crisis of medicine has been even more 
marked by the changes in the relationship be-
tween doctor and patient, a relationship from 
the remote past, starting from to the Hippo-
cratic Oath, despite the Hippocratic principles 
are very current. Beyond the specific principles 
and contents, however, the Hippocratic Oath 
highlights the strong relational character, aimed 
at guaranteeing unconditional respect for the 
person at the weakest end of the care relation-
ship. Moreover, the Hippocratic care relation-
ship is strongly characterized by an asymmet-
rical distribution of resources between the per-
son receiving the care and the person providing 
it, with the former totally subject to the latter. 
This asymmetry, inherent in the technical con-
tents of the treatment, producing a radical dis-
tance between those who administer the treat-
ment and those who receive it, is not, however, 
an asymmetry that hinders relationality. In fact, 
it does not lead to prevaricating outcomes, 
while it should lead to concrete positive solu-
tions, as the result of a real cooperative spirit. 
(Ruggeri, 2010, 17).  
The relational asymmetry that emerges from 
the doctor-patient relationship is a constant el-
ement of any power relationship, as highlighted 
also in the foucaultian genealogical reconstruc-
tion. If this asymmetry, in the context of sover-
eignty, was clearly structured between the sov-
ereign and his subjects, nevertheless it remains 
in the biopolitical perspective. Life, even 
though it is no longer subject to that power of 
life and death that acts by taking it, is managed 
because of relationships within a fundamental 
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asymmetry between those who hold the truth 
and knowledge, and those who are subject to it. 
Obviously, even the doctor-patient relationship 
is not exempt from this mechanism. The medi-
calization of society itself has been possible by 
subjects possessing medical knowledge and 
considered authoritative. They were able to in-
duce certain behaviors and manage certain dy-
namics into the society. However, the doctor-
patient relationship, sometimes defined as pa-
ternalistic, provided that the doctor had the 
power to treat but, at the same time, to choose 
the therapy considered most suitable for the 
case in question. The only limit to this power 
was the fact that the choice had to be made in 
science and conscience, with the patient's will 
practically nil (Grassini and Pacifico 2012, 14). 
It was only later that the so-called informed 
consent had on a crucial role. It finds its begin-
ning during medical experimentations, con-
ducted at the beginning of the 20th century. It 
acquired its greatest fame in the Nuremberg 
process, from which arose in 1946 the Nurem-
berg Code, which states the principle that "the 
voluntary consent of the human being is essen-
tial". 
It is however important to underline that this 
Code was developed as a response to the abus-
es carried out in the extermination camps dur-
ing the Second World War, highlighting how 
experimentation was not a strictly therapeutic 
activity, but that it had the potential to cause 
physical and psychophysical injuries to individ-
uals. 
A different case was in the traditional medical 
practice, which was not prosecuted in Nurem-
berg, where the activity of the doctor, aimed at 
identifying and treating a certain disease follow-
ing a more or less safe therapy, was justified on 
the basis of a state of need, real or supposed 
(13). It is only in the last decades that the prin-
ciple of informed consent has firmly established 
in the relationship between doctor and patient, 
ratifying the end of the paternalistic relationship 
and the advent of the autonomy of the patient. 
It was also expressed by the National Commit-
tee for Bioethics in its 1992 Opinion "Infor-
mation and consent to the medical act", which 
also revealed the close link between the consent 
that the patient must give and the information 
that is provided to him. 
The philosopher and sociologist Jürgen 
Habermas, referring to the Freudian analysis of 
the therapeutic dialogue between doctor and 
patient, has taken up the peculiarity of the 
asymmetrical relationship in the distribution of 
roles, linking it to the potential of communica-
tive action. In this perspective, he defines 
"therapeutic criticism" a form of argument that 
can solve cases of self-deception, to which the 
patient is often victim (Habermas 1997, 78). 
This is evident in the relationship between the 
psychotherapist and the patient, where the lat-
ter is induced to reflect on himself and on his 
own situation. Thus, the behavior of a subject 
appears rational when he can rid himself of his 
own illusions, that are not the result of an error, 
but rather of a form of self-deception. For this 
purpose, it is essential that the patient first ac-
quires an opening towards those who can shed 
light on what, at least initially, appears to be a 
form of irrationality. A rational attitude presup-
poses a willingness to understand and, if there 
are communication disorders, also a reflection 
on linguistic rules. 
This reflection can be extended to any profes-
sional doctor-patient relationship and to all 
those situations in which the difference be-
tween the patient's self-deception and the phy-
sician's knowledge is most evident. The concept 
of communicative action becomes crucial. It is 
realized every time that an interpersonal rela-
tionship is established between at least two sub-
jects capable of action and language (with ver-
bal or extra-verbal forms). The main aim is to 
reach an understanding that leads to a common 
agreement on the action plans to pursue. Lan-
guage, in this process, is fundamental because 
the level of interpretation of specific situations 
susceptible to consensus depends on it (157). 
The communication process has clearly become 
indispensable in order to proceed to any medi-
cal act, as also underlined by the Code of Medi-
cal Deontology in art. 33, which highlights the 
duty of the doctor to provide the patient with 
detailed information on the diagnosis and pro-
spects of intervention and treatment. 
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From informed consent to defensive medi-
cine 
 
The singular and in some ways surprising fact, 
therefore, emerges from the history of the doc-
tor-patient relationship, especially with refer-
ence to the historical period that began in the 
twentieth century. In such period, medicine ac-
quired a great therapeutic security, attributing to 
doctors, for the first time in history, the power 
to effectively treat common diseases. Paradoxi-
cally, at this very juncture, the doctor-patient 
relationship cracked, risking compromising the 
prestige that doctors had enjoyed until then. 
Prestige and medical authority, moreover, 
played a fundamental symbolical role as indica-
tors of the ability and power of a doctor to 
transmit confidence during his work and in the 
possibility of recovery to the patient. 
Foucault, reflecting on the possibilities that sci-
ence and medicine offered to populations, es-
pecially since the second half of the last centu-
ry, highlighted how the current medical tools 
have different effects on population. Although 
they are not generally considered harmful, tools 
can nevertheless be incontrollable, forcing the 
human species to enter a dangerous history, in-
to a field of probability and risks the extent of 
which cannot be precisely measured. The phi-
losopher from Poitiers emphasized that, alt-
hough the medical risk, that is the difficult con-
nection to break between positive and negative 
effects of medicine, is not a novelty, today this 
risk has entered a new dimension. It is no long-
er imputable only to the treated subject or to its 
descendants, but to the entire human species. 
The possibility of medical and genetic interven-
tions on DNA has placed life in its entirety (no 
longer the life of an individual or a specific 
population) in the field of medical impacts, 
marking the entrance into what Foucault de-
fines as bio-history. In this dimension, human 
history can modify life and can exert fundamen-
tal effects on its process. This can determine 
one of the main risks of current medicine, the 
problems of communication from doctors to 
patients (and “vice-versa”), in addition to the 
technical anxiety that doctors and biologists feel 
about their practice and their knowledge. 
Apart from the crisis resulting from these dy-
namics, Foucault believed that there is also the 
phenomenon of indefinite medicalization, 
which has led medicine to act outside its tradi-
tional field, going beyond the encounter with 
the patient and the disease. Medicine is increas-
ingly proposed as an act of authority, regardless 
of the patient's demand (for example, screening 
policies or the role that doctors and psychia-
trists play both in the workplace and in the ju-
diciary). Finally, the subject of medical interven-
tion is no longer exclusively illness, but health 
in the broadest sense. Thus, all medical inter-
ventions, that in general are aimed to improve 
the health conditions of individuals, respect the 
principle that the preponderance given to the 
disease has become a form of general regulation 
of society. 
Lastly, Foucault considered among the charac-
teristics of modern medicine what he defines as 
the "political economy of medicine". It would 
not be a novelty, meaning that from the begin-
ning it was precisely the economic problems 
that determined the medical organization. 
However, while in the past medicine was as-
sumed as an instrument of conservation and 
renewal of the workforce for the functioning of 
modern society, today it directly produces wel-
fare to the extent that health represents a desire 
for one and a luxury for the others. Health has 
effectively become an object of consumption 
and has become a market product. As a result, 
the body has also entered the market twice, 
once by wages, when it has sold its workforce, 
and once by health, where the body comes to 
be an object of sensations and desires. Incite-
ment to prevention, empowerment and optimi-
zation (different screenings, healthy eating reg-
imens, not smoking, improving own individual 
performance, etc.) cannot, however, be ad-
dressed to everyone. This inevitably is the price 
to be paid, taking the form of exclusive and ex-
clusionary medicalization (Bazzicalupo 2006, 
111-113). 
In addition, rapid technological and scientific 
progress has also led to the reduced perception 
of death as a possible outcome of the disease, 
but rather as an avoidable complication. This 
led to paradoxically believe that, in the event of 
an unfortunate outcome, it is the doctor who 
handled the clinical case who has committed a 
mistake and must pay. 
Inevitably, there has been a fracture of the doc-
tor-patient relationship, to which many factors 
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have contributed, including the progressive bu-
reaucratization of medical services, the process 
of technocratic and political transformation of 
the health organization, the increasing costs of 
care. These factors determine the consequent 
recourse to the assessment of health costs and 
benefits for patients, and finally the progressive 
abandonment of the physical approach to the 
patient, replaced by clinical investigation and by 
the growing use of technological tools. 
Moreover, the increasingly predominant role of 
the economy and the costs in the current health 
has become more evident, transforming hospi-
tals into "Health Authorities", in which the 
health of citizens is a product or rather a com-
modity, correlated with the payment and/or the 
refund by the state for hospital services. Con-
sequently, even ethical values are continuously 
questioned and often subordinated to economic 
interests. 
These changes have led, especially in recent 
times, to a growing level of complaints related 
to so-called "malpractice" cases. Claims arising 
either from patients’ greater awareness of health 
care, or from a considerable increase of eco-
nomic compensations established in court-
rooms, led to a greater readiness by the public 
to appeal to jurisprudence for medical ligations. 
The increase in awareness of the right to health 
when receiving treatment and in expectations 
of public health facilities has perhaps reached 
excessive and often unjustified levels. So that 
medical treatment, which does not produce the 
desired clinical outcome, is often interpreted by 
the patient as a mistake, whereas it can simply 
be scientifically impossible. 
Currently, an increasing number of patients use 
internet to search for diagnoses and treatments 
(the “e-doctor” phenomenon) going after that 
to the family doctor or a specialist to confirm 
their results. By these dangerous behaviors, 
many potential patients consider internet as a 
substitute for the family doctor.  
The most obvious consequence of this situation 
is that doctors are increasingly relying on defen-
sive medicine, allowing their diagnostic and 
therapeutic strategies to be conditioned by "ju-
dicial caution" rather than by their scientific be-
liefs. This has a serious economic impact, re-
sulting from the excessive provision of care and 
unnecessary recourse to tests and clinical exam-
inations.  
In addition to the doctor's fear to be dragged in 
a court by patients, another reason for defen-
sive medicine increasing phenomenon is the 
poor organization of complex health structures, 
in which the reference protocols do not ade-
quately specify roles and responsibilities. 
The burden of each judicial case therefore falls 
on the individual doctor, who is the last link in 
the chain of organization of the health system. 
Consequently, doctors daily face with bigger 
problems than themselves and resort to defen-
sive medicine, which is just an attempt to share 
the burden of responsibility with others. 
Another consequence of the increase in claims 
on malpractice is the growing cost of insurance 
premiums, so much so that recent political pro-
posals on medical claims go in the direction of 
translating in the civil right rather than criminal 
process. This would lead to an increase in in-
surance premiums, the cost of which would not 
be charged to the individual doctors but to the 
health facility in which they operate. These in-
surance policies would encourage risk manage-
ment, adequately supported by the health ser-
vice, in order to reduce unfair practices and 
thus keep insurance premiums to a minimum.  
Risk management considers all the huge medi-
cal complex activities, undertaken to improve 
the quality of health care and ensure patient 
safety. Only a proper risk management can lead 
to substantial changes in clinical practice, mak-
ing it more suitable to the needs of both pa-
tients and healthcare professionals (Toraldo, 
Vergari and Toraldo 2015). 
Already in December 2001, the National Bio-
ethics Committee (NBC), in an opinion on 
"Purposes, Limits and Risks of Medicine", 
demonstrated that medical failures are often the 
most visible aspects of medical practice in the 
wider sectors of the population. They generate 
collective reactions expressed and amplified by 
the media, with legal consequences and de-
mands for individual damages. 
The solution to these problems lies first in edu-
cating the public of potential patients. The in-
volvement of society requires ethical communi-
cation addressed to all citizens, designed to in-
form them about the nature, possibilities, limits 
and risks of modern medicine, both in scientific 
than in practical terms. Adequate communica-
tions mean to provide transparent information 
and news, even when they are unpleasant or 
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disappointing. Only in a context of effective 
transparency is possible, according to NBC, to 
find solutions to legal and bioethical issues, 
concerning medical responsibility and of strong 
social relevance. 
It would be essential for all the media to con-
sider their aim to correctly inform citizens, also 
highlighting the differences that, in health 
terms, inevitably arise in the various geograph-
ical, technological and logistical contexts.
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